Document:

Amended and Restated Stockholders Agreement

 Exhibit 10.2 
 EXECUTION COPY 
 AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT 
 AMENDED AND RESTATED STOCKHOLDERS AGREEMENT, dated as of
December 21, 2006, by and among US ONCOLOGY HOLDINGS, INC. (formerly known as Oiler Holding Company), a Delaware corporation (the “Company”), WELSH, CARSON, ANDERSON & STOWE IX, L.P., a Delaware limited partnership
(“WCAS IX”), MORGAN STANLEY STRATEGIC INVESTMENTS, INC., a Delaware corporation (“Morgan Stanley”), and each of the other individuals and entities from time to time named on Schedule I hereto (together with
WCAS IX and Morgan Stanley, and together with their respective Permitted Transferees and their respective successors and assigns that become a party to this Agreement in accordance with the terms hereof, each a “Stockholder” and
collectively, the “Stockholders”). 
 RECITALS 
 WHEREAS, the Company, WCAS IX and certain other Stockholders entered into the original Stockholders Agreement, dated as of August 20, 2004 (the
“Original Stockholders Agreement”), to provide for certain matters relating to the shares of Participating Preferred Stock, par value $0.001 per share, of the Company (the “Series A Preferred Stock”), and the shares
of Common Stock, par value $0.001 per share, of the Company (“Company Common Stock”), in each case, held by such Stockholders; 
 WHEREAS, the Company and Morgan Stanley have entered into a Stock Purchase Agreement, dated as of December 21, 2006 (the “Stock Purchase Agreement”), pursuant to which the Company has agreed to sell to Morgan Stanley
shares of Series A-1 Participating Preferred Stock, par value $0.001 per share, of the Company (the “Series A-1 Preferred Stock” and together with the Series A Preferred Stock, the “Company Preferred Stock”) and
shares of Company Common Stock; and 
 WHEREAS, in connection with the investment contemplated by the Stock Purchase Agreement, the Company,
WCAS IX and certain other Stockholders wish to amend and restate the Original Stockholders Agreement in the manner set forth herein; 
 NOW,
THEREFORE, in consideration of the premises and of the mutual covenants and agreements herein contained, the parties hereto hereby agree as follows: 
 ARTICLE I. 
 INTRODUCTORY MATTERS 
 SECTION 1.01. Defined Terms. In addition to the terms defined elsewhere herein, the following terms have the following meanings when used herein with initial capital letters: 
 “Affiliate” means, with respect to any specified Person, a Person that directly, or indirectly through one or more intermediaries,
Controls, is Controlled by or is under common Control with, the specified Person; provided, that officers, directors or employees of the Company or USON will not be deemed to be Affiliates of a stockholder of the Company for purposes hereof
solely by reason of being officers, directors or employees of the Company or USON; provided, further, that, for purposes of Section 8.02(vi) and the definition of Third Party contained in Section 4.01, no portfolio company of
WCAS IX (or of any other investment partnership under common control with WCAS IX) shall be deemed to be an Affiliate of the Company or WCAS IX unless a majority of the outstanding voting securities or 25% or more of the economic interests of such
portfolio company are owned, directly or indirectly, by WCAS IX and/or such other investment partnership. 
  

 1 

 “Agreement” means this Agreement, as the same may be amended, supplemented or otherwise
modified from time to time in accordance with the terms hereof. 
 “Assumption Agreement” means a writing reasonably
satisfactory in form and substance to the Company and WCAS IX whereby a Permitted Transferee of Company Equity Securities becomes a party to, and agrees to be bound (to the same extent as its transferor) by, the terms of this Agreement as a
“Stockholder” hereunder. 
 “Board” means the Board of Directors of the Company. 
 “Business Day” means a day other than a day on which commercial banks in New York, New York or Houston, Texas are authorized or required
by law to close. 
 “Commission” means the Securities and Exchange Commission, or any other federal agency at the time
administering the Securities Act. 
 “Company Capital Stock” means the Company Common Stock, the Company Preferred Stock and
any other class or series of capital stock or other equity stock of the Company. 
 “Company Certificate” means the Second
Amended and Restated Certificate of Incorporation of the Company, as amended, restated or modified. 
 “Company Equity
Securities” means all shares of Company Capital Stock now or hereafter issued and all Options or Convertible Securities now or hereafter issued. 
 “Company Stock Plans” means all stock option plans, restricted stock purchase plans and other stock-based employee benefit plans and agreements approved by the Board, including the Company’s 2004
Equity Incentive Plan. 
 “Control” (including the terms “Controlling”, “Controlled by”
and “under common Control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or
otherwise. 
  

 2 

 “Designated Affiliate” means (i) in the case of any Stockholder that is not a
natural person, any Affiliate of such Stockholder, (ii) in the case of a Stockholder who is a natural person, such Stockholder’s parents, spouse and lineal descendants and the lineal descendants of such Stockholder’s spouse, or trusts
for the benefit of, or corporations, limited liability companies or partnerships, the stockholders, members or general and/or limited partners of which include, only such Stockholder and/or Stockholder’s parents, spouse or lineal descendants or
the lineal descendants of such Stockholder’s spouse, (iii) in the case of WCAS IX and each of its Designated Affiliates under this clause (iii), WCAS IX and each general or limited partner, manager, member, officer, director or employee
thereof, and (iv) in the case of Morgan Stanley and each of its Designated Affiliates under this clause (iv), Morgan Stanley and each stockholder, partner, manager, member, director or officer thereof. For purposes of the foregoing, lineal
descendants shall be deemed to include children by adoption. 
 “Exchange Act” means the Securities Exchange Act of 1934, or
any successor federal statute, and the rules and regulations of the Commission thereunder, as the same may be amended from time to time. 
 “Fully Diluted Basis” means, with respect to any determination of the number of shares of Company Common Stock outstanding or held by one or more Persons, the number of shares of Company Common Stock outstanding or held by
such Persons (excluding any unvested shares of restricted Company Common Stock issued under Company Stock Plans) assuming (i) the conversion of each outstanding share of Company Preferred Stock into that number of shares of Company Common Stock
equal to the Conversion Constant (as defined in Section I of Article FOURTH of the Company Certificate) as in effect at the time of such determination and (ii) the full conversion, exercise and exchange of all other Options or Convertible
Securities for Company Common Stock (excluding options and other rights issued under Company Stock Plans and excluding any other Options or Convertible Securities which are not exercisable or which have not vested or shares received upon the
exercise of such Options or Convertible Securities which would not be vested); provided, however, that in connection with a Proposed Sale (as defined in Section 3.01(a)), unvested shares of restricted Company Common Stock issued
under Company Stock Plans which would vest at or before the consummation of such Proposed Sale shall not be excluded from the determination of the number of shares of Company Common Stock held by a Tagging Stockholder; provided,
further, however, that in connection with determining whether a Stockholder is a Qualified Stockholder or determining a Qualified Stockholder’s Proportionate Percentage for purposes of Article V, unvested shares of restricted
Company Common Stock issued under Company Stock Plans shall not be excluded from the determination of the number of shares of Company Common Stock held by such Stockholder. 
 “Options or Convertible Securities” means any securities (including, without limitation, any options, warrants or other rights) which
are directly or indirectly convertible into or exercisable or exchangeable for Company Capital Stock. 
 “Permitted
Transferee” means any (i) Person to whom Company Equity Securities are Transferred in a Transfer in accordance with Section 2.02 and otherwise not in violation of this Agreement and who enters into an Assumption Agreement and
(ii) Person to whom Company Equity Securities are Transferred by any Stockholder in a Transfer in accordance with Section 2.01(a)(i) who agrees in writing to become a party to and agrees to be bound (to the 

  

 3 

 
same extent as its transferor) by, the terms of this Agreement as a “Stockholder” hereunder, it being understood, in each case, that neither the
Company nor any of its Subsidiaries shall be considered to be Permitted Transferees. 
 “Person” means any natural person,
corporation, limited liability company, partnership, trust, joint stock company, business trust, unincorporated association, joint venture, governmental authority or other legal entity of any nature whatsoever. 
 “Public Offering” means the sale of shares of Company Common Stock to the public pursuant to an effective registration statement (other
than a registration statement on Form S-4, Form S-8 or any similar or successor form) filed under the Securities Act. 
 “Qualified
Merger” means the consummation of any sale of all then outstanding Company Equity Securities (whether by means of a merger or otherwise), or sale of all or substantially all of the Company’s assets to, a Third Party, if the holders of
shares of Company Equity Securities, as consideration for such sale, directly or indirectly, receive equity securities which are tradable on a national securities exchange (i) without further registration under the Securities Act and
(ii) without being subject to any volume limitations set forth in Rule 144 promulgated under the Securities Act. 
 “Qualified
Public Offering” means any firm commitment underwritten Public Offering in which the aggregate proceeds to the Company (together with the aggregate proceeds in all such prior public offerings) are at least $100.0 million. 
 “Qualified Stockholder” means any Stockholder who (individually or together with its Designated Affiliates), at the time of
determination, holds on a Fully Diluted Basis not less than 500,000 shares (as adjusted for any stock splits, stock dividends, stock combinations and similar events occurring after the date hereof) of Company Common Stock. 
 “Schedule IV Purchaser” means any Schedule IV Purchaser under and as defined in the Stock Subscription Agreement (which Stockholders are
listed on Schedule I hereto under the heading “Schedule IV Purchasers”) so long as such Stockholder continues to own, collectively with its Permitted Transferees, at least 50% of the shares of Company Common Stock and 50% of the
shares of Company Preferred Stock owned by it on August 20, 2004 after giving effect to the transactions contemplated by the Stock Subscription Agreement. 
 “Securities Act” means the Securities Act of 1933, or any successor federal statute, and the rules and regulations of the Commission thereunder, as the same may be amended from time to time.

 “Stock Subscription Agreement” means the Stock Subscription and Exchange Agreement, dated as of August 20, 2004, by
and among the Company, WCAS IX and certain Stockholders. 
 “Subsidiary” of a Person means any Person of which equity
securities or other ownership interests having ordinary voting power to elect a majority of the board of directors, the general partner, the manager or other Persons performing similar functions are at the time 

  

 4 

 
directly or indirectly owned by the Person. Unless the context otherwise requires, references to one or more Subsidiaries are references to Subsidiaries of
the Company. 
 “Transfer” means a transfer, sale, assignment, pledge, hypothecation or other disposition (including by
operation of law), whether directly or indirectly pursuant to the creation of a derivative security, the grant of an option or other right or the imposition of a restriction on disposition or voting. 
 “USON” means US Oncology, Inc., a Delaware corporation, and a wholly owned Subsidiary of the Company. 
 “Voting Proxy” means any irrevocable proxy granted to WCAS IX by a Stockholder and shall include each “Voting Proxy” referred
to in the Stock Subscription Agreement. 
 SECTION 1.02. Construction. (a) The parties hereto have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring
or disfavoring any party by virtue of the authorship of any provisions of this Agreement. Unless the context otherwise requires: (i) “or” is disjunctive but not exclusive, (ii) words in the singular include the plural, and
in the plural include the singular, (iii) the words “hereof”, “herein”, and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any
particular provision of this Agreement, (iv) the headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement, (v) the words “Article” and
“Section” are references to the articles and sections of this Agreement unless otherwise specified and (vi) whenever the words “include”, “includes” or “including” are used in this
Agreement they shall be deemed to be followed by the words “without limitation”. 
 (b) References herein to WCAS IX, to the extent
such entity shall have transferred any of its shares of Company Capital Stock to one or more Permitted Transferees, shall mean WCAS IX and such Permitted Transferees, taken together, and any right or action that may be taken at the election of WCAS
IX may be taken at the election of WCAS IX and such Permitted Transferees to the extent WCAS IX has agreed in writing to transfer such rights to any such Permitted Transferee. 
 (c) References herein to Morgan Stanley, to the extent such entity shall have transferred any of its shares of Company Capital Stock to one or more
Permitted Transferees, shall mean Morgan Stanley and such Permitted Transferees, taken together, and any right or action that may be taken at the election of Morgan Stanley may be taken at the election of Morgan Stanley and such Permitted
Transferees to the extent Morgan Stanley has agreed in writing to transfer such rights to any such Permitted Transferee. 
  

 5 

 ARTICLE II. 
 TRANSFERS 
 SECTION 2.01. Transfers. (a) No Stockholder may Transfer any Company Equity
Securities other than: 
 (i) with respect to Transfers by Stockholders other than by WCAS IX, Transfers made with the written
consent of WCAS IX; provided, that, notwithstanding the foregoing, any employee, officer or director of the Company or any of its subsidiaries may Transfer Company Equity Securities to the Company or any of its Subsidiaries; provided,
further, that notwithstanding the foregoing, in the case of any proposed Transfer by Morgan Stanley or any of its Permitted Transferees after the third anniversary of the date hereof, such written consent of WCAS IX will not be unreasonably
withheld, delayed or conditioned; 
 (ii) Transfers made in accordance with Section 2.02; 
 (iii) Transfers made in accordance with Article III (including any Excluded Transactions (as defined in Section 3.01(a)); or

 (iv) Transfers made in accordance with Article IV. 
 Any attempted Transfer of Company Equity Securities in violation of the provisions of this Agreement shall be null and void ab initio and of no effect. 
 (b) Each certificate representing Company Equity Securities that is held by a Stockholder will bear a legend substantially to the following effect with
such additions thereto or changes therein as the Company may be advised by counsel are required by law or necessary to give full effect to this Agreement (the “Stockholders Agreement Legend”): 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A STOCKHOLDERS AGREEMENT, AMENDED AND RESTATED AS OF DECEMBER 21, 2006, AMONG THE
COMPANY AND THE OTHER PARTIES THERETO, AS AMENDED, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. NO TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY BE MADE
EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF SUCH STOCKHOLDERS AGREEMENT. THE HOLDER OF THIS CERTIFICATE, BY ACCEPTANCE OF THIS CERTIFICATE, AGREES TO BE BOUND BY ALL OF THE PROVISIONS OF SUCH STOCKHOLDERS AGREEMENT.” 
 The Stockholders Agreement Legend will be removed by the Company by the delivery of substitute certificates without such Stockholders Agreement Legend in the event of
(i) a Transfer permitted by this Agreement in which the Transferee is not required to enter into an Assumption Agreement or (ii) the termination of this Agreement in accordance with Section 10.07. 
  

 6 

 (c) The Company shall not give effect to any attempted Transfer of Company Equity Securities made in
violation of the terms of any Voting Proxy, and any attempted Transfer in violation of the terms thereof shall be null and void ab initio and of no effect. At all times prior to the expiration of any Voting Proxy, the Company shall use its
best efforts to comply with the provisions of such Voting Proxies relating to the placing of legends on Company Equity Securities, and each Stockholder granting any such Voting Proxy hereby consents to the placing of such legends on such
certificates. 
 SECTION 2.02. Transfers to Permitted Transferees. Any Stockholder may, at any time, Transfer any or all of the
Company Equity Securities held by such Stockholder to any one or more Designated Affiliates of such Stockholder so long as each such Designated Affiliate duly executes and delivers an Assumption Agreement (such Transfer to be effective only upon the
delivery of such Assumption Agreement to the Company and WCAS IX); provided, that if the Company so requests promptly following (and, in any event, within five (5) Business Days after) its receipt of such Assumption Agreement, such
Assumption Agreement shall not be effective unless and until the Company has been furnished with an opinion in form and substance reasonably satisfactory to the Company of counsel reasonably satisfactory to the Company that such Transfer is exempt
from or not subject to the provisions of Section 5 of the Securities Act and any other applicable securities laws. Notwithstanding the foregoing, no party hereto shall avoid the provisions of this Agreement by making one or more Transfers to
one or more Permitted Transferees and then disposing of all or any portion of such party’s interest in any such Permitted Transferee. 
 SECTION 2.03. Securities Law Compliance. (a) Each Stockholder agrees that it will not effect any Transfer of Company Equity Securities held by such Stockholder unless such Transfer is made pursuant to an effective registration
statement under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and, in either case, in compliance with all applicable state securities laws. The Company
agrees, and each Stockholder understands and consents, that (i) the Company will not cause or permit the Transfer of any Company Equity Securities to be made on its books (or on any register of securities maintained on its behalf) unless the
Transfer is permitted by, and has been made in accordance with the terms of this Agreement and all applicable federal and state securities laws and (ii) no Transfer of Company Equity Securities under this Article II shall be permitted if such
Transfer would require the Company to register a class of equity securities under Section 12 of the Exchange Act under circumstances where the Company does not then have securities of any class registered under Section 12 of the Exchange
Act. Any attempted Transfer in violation of the terms hereof shall be null and void ab initio and of no effect. Each Stockholder agrees that in connection with any Transfer of Company Equity Securities that is not made pursuant to a
registered public offering, the Company may, in its sole discretion, request an opinion in form and substance reasonably satisfactory to the Company of counsel reasonably satisfactory to the Company stating that such transaction is exempt from
registration under the Securities Act and in compliance with applicable state securities laws. 
 (b) From and after the date hereof, and
until such time as such securities have been sold to the public pursuant to an effective registration statement under the Securities Act or pursuant to an exemption from such registration and the holder of such securities shall have requested the
issuance of new certificates in writing and, if requested by the Company, delivered 

  

 7 

 
to the Company an opinion in form and substance reasonably satisfactory to the Company of counsel reasonably satisfactory to the Company to such effect, all
certificates representing Company Equity Securities that are held by any Stockholder shall bear a legend which shall state the following: 
 “THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND NO INTEREST HEREIN MAY BE SOLD, OFFERED, ASSIGNED, DISTRIBUTED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS
(A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING ANY SUCH TRANSACTION OR (B) THE COMPANY RECEIVES AN OPINION IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY OF COUNSEL REASONABLY SATISFACTORY TO THE
COMPANY STATING THAT SUCH TRANSACTION IS EXEMPT FROM SUCH REGISTRATION AND IN COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES LAWS OR (C) THE COMPANY AND ITS COUNSEL ARE OTHERWISE SATISFIED THAT SUCH TRANSACTION IS EXEMPT FROM SUCH REGISTRATION
AND IN COMPLIANCE WITH ALL STATE SECURITIES LAWS.” 
 ARTICLE III. 
 TAG-ALONG RIGHTS 
 SECTION 3.01. Tag-Along Rights. (a) With respect
to any proposed Transfer by WCAS IX and/or any of its Permitted Transferees (collectively, the “Selling Stockholder”) of shares of Company Capital Stock to any Person who is not a Designated Affiliate of the Selling Stockholder
other than (i) pursuant to any agreement or plan of merger or combination, including any tender or exchange offer in respect thereof, that is approved by the Board and does not involve a disproportionate Transfer by the Selling Stockholder of
shares of the applicable class of Company Capital Stock or (ii) any transaction or transactions for strategic purposes that (when aggregated with all shares sold in connection with prior Transfers that were deemed to be Excluded Transactions
under this clause (ii)) result in the Transfer by the Selling Stockholder since August 20, 2004 of (x) less than an aggregate 1,069,106 (as adjusted for any stock splits, stock dividends, stock combinations and similar events occurring
after August 20, 2004) shares of Company Preferred Stock and/or (y) less than an aggregate 7,483,744 shares (as adjusted for any stock splits, stock dividends, stock combinations and similar events occurring after August 20, 2004) of
Company Common Stock (any such transaction referred to in clause (i) or (ii) above, an “Excluded Transaction”, and any such transaction not excluded under clause (i) or (ii) above, a “Proposed
Sale”), each Stockholder (other than the Selling Stockholder) who exercises its rights under this Section 3.01(a) in accordance with this Section 3.01 (each a “Tagging Stockholder”) will have the right to include
the following in the proposed sale to the proposed transferee(s) of shares (the “Proposed Transferee”) or sell the following to the Selling Stockholder (if such Proposed Transferee will not agree to purchase shares directly from
such Tagging Stockholder, and in such case the Selling Stockholder shall be obligated to purchase from such Stockholder the following): (1) if the Selling Stockholder proposes to Transfer shares of Company Preferred Stock in such Proposed Sale,
a number of shares of Company Preferred Stock up to the product (rounded down to the nearest whole number) of (i) the quotient 

  

 8 

 
determined by dividing (A) the aggregate number of shares of Company Preferred Stock owned by such Tagging Stockholder by (B) the aggregate number
of shares of Company Preferred Stock then outstanding and (ii) the total number of shares of Company Preferred Stock proposed to be Transferred to the Proposed Transferee(s) and/or (2) if the Selling Stockholder proposes to Transfer shares
of Company Common Stock in such Proposed Sale, a number of shares of Company Common Stock up to the product (rounded down to the nearest whole number) of (i) the quotient determined by dividing (A) the aggregate number of shares of Company
Common Stock owned by such Tagging Stockholder on a Fully Diluted Basis by (B) the aggregate number of shares of Company Common Stock then outstanding on a Fully Diluted Basis and (ii) the total number of shares of Company Common Stock
proposed to be Transferred to the Proposed Transferee(s), at the same price(s) per share of Company Preferred Stock and/or Company Capital Stock, as the case may be, and upon the same terms and conditions (including time of payment, form of
consideration and adjustments to purchase price) as the Selling Stockholder; provided, that in order to be entitled to exercise its right to sell shares of Company Capital Stock to the Proposed Transferee pursuant to this Section 3.01,
each Tagging Stockholder (x) shall agree to the same covenants as the Selling Stockholder agrees to in connection with the Proposed Sale, (y) shall be obligated to join on a pro rata (and several) basis (based on the proceeds
received by such Tagging Stockholder in connection with the Proposed Sale) in any indemnification that the Selling Stockholder agrees to provide in connection with the Proposed Sale (other than in connection with obligations that relate to a
particular Stockholder such as representations and warranties concerning itself for which each Stockholder shall agree to be solely responsible, and provided further that the liability for any such pro rata (and several)
indemnification obligations shall not exceed the total consideration received by such Stockholder for such shares), and (z) shall make such representations and warranties concerning itself and the shares of Company Capital Stock to be sold by
it in connection with such Transfer as the Selling Stockholder makes with respect to itself and its shares (such terms and conditions of any Proposed Sale being the “Tag-Along Terms”). 
 (b) Each Tagging Stockholder will be responsible for funding its proportionate share of any adjustment in purchase price or escrow arrangements in
connection with the Proposed Sale and for its proportionate share of any withdrawals from any such escrow, including any such withdrawals that are made with respect to claims arising out of agreements, covenants, representations, warranties or other
provisions relating to the Proposed Sale. 
 (c) Each Tagging Stockholder will be responsible for its proportionate share of the fees,
commissions and other out-of-pocket expenses (collectively, “Costs”) of the Proposed Sale to the extent not paid or reimbursed by the Company, the Proposed Transferee or another Person (other than the Selling Stockholder);
provided, that the liability for such Costs shall not exceed the total purchase price received by such Stockholder for such shares (or if such Proposed Sale does not occur, such proposed purchase price). The Selling Stockholder shall be
entitled to estimate each Tagging Stockholder’s proportionate share of such Costs and to withhold such amounts from payments to be made to each Tagging Stockholder at the time of closing of such Proposed Sale; provided, that
(i) such estimate shall not preclude the Selling Stockholder from recovering additional amounts from the Tagging Stockholders in respect of each such Tagging Stockholder’s proportionate share of such Costs and (ii) the Selling
Stockholder shall reimburse each Tagging Stockholder to the extent actual amounts are 

  

 9 

 
ultimately less than the estimated amounts or any such amounts are paid by the Company, the Proposed Transferee or another Person (other than the Selling
Stockholder). 
 SECTION 3.02. Exercise of Tag-Along Rights; Notices. The Selling Stockholder will give the Company prior written
notice of each Proposed Sale, setting forth the number and type of shares of Company Capital Stock proposed to be so Transferred, the name and address of the Proposed Transferee, the proposed amount and form of consideration and other material
Tag-Along Terms offered by the Proposed Transferee. In the event that any of the material terms or conditions set forth in the notice are thereafter amended in any material respect, the Selling Stockholder shall also give written notice of the
amended terms and conditions of the Proposed Sale to the Company. Upon its receipt of any such notice or amended notice, the Company shall promptly, but in all events within two (2) Business Days of its receipt thereof, forward copies thereof
to each of the Stockholders other than the Selling Stockholder (such initial notice, the “Tag-Along Opportunity Notice” and any amended notice, an “Amended Tag-Along Opportunity Notice”). In order to exercise the
tag-along rights provided by this Article III a Stockholder must send a written notice to the Company and the Selling Stockholder indicating its desire to exercise its rights and specifying the number and type of shares of Company Capital Stock it
desires to sell (the “Tag-Along Exercise Notice”) within ten (10) days following the receipt of the Tag-Along Opportunity Notice by such Stockholder (or if an Amended Tag-Along Opportunity Notice is given to the Stockholders
within such ten (10) day period, within five (5) days following the receipt of such Amended Tag-Along Opportunity Notice by such Stockholder). Upon the receipt of an Amended Tag-Along Opportunity Notice by a Stockholder that had previously
provided a Tag-Along Exercise Notice, such Tagging Stockholder shall be permitted to cancel its exercise of its rights under this Article III upon delivery of written notice to the Selling Stockholder and the Company to such effect and shall be
released from its obligation hereunder. There shall be no liability on the part of the Selling Stockholder to any Tagging Stockholder if the sale of shares of Company Capital Stock pursuant to this Article III is not consummated for whatever reason.
Whether or not to effect a sale of shares of Company Capital Stock pursuant to this Article III shall be within in the sole and absolute discretion of the Selling Stockholder. 
 SECTION 3.03. Closing of Proposed Sale. (a) Each Tagging Stockholder shall deliver to the Company, as agent for such Tagging Stockholder, for
transfer to the Proposed Transferee one or more certificates, properly endorsed for transfer and with all stock transfer taxes paid and stamps affixed, which represent the shares of Company Capital Stock that such Tagging Stockholder is permitted to
dispose of pursuant to this Article III. The consummation of such Proposed Sale shall be subject to the sole discretion of the Selling Stockholder, who shall have no liability or obligation whatsoever to any Tagging Stockholder participating therein
other than to obtain for such Tagging Stockholder the same Tag-Along Terms as those of the Selling Stockholder. In connection with the consummation of any such Proposed Sale, the Company (i) shall transfer to the Proposed Transferee at the
closing of such Proposed Sale a stock certificate or certificates representing the shares of Company Capital Stock to be disposed of by any Tagging Stockholders and (ii) shall promptly thereafter remit to each Tagging Stockholder (x) that
portion of the proceeds of the disposition to which such Tagging Stockholder is entitled by reason of such participation (after giving effect to Section 3.01(b) and/or 3.01(c)) and (y) a stock certificate or certificates representing any
balance of shares of Company Capital Stock that were not so disposed of (or all shares of Company Capital Stock, in the event the proposed disposition 

  

 10 

 
is not consummated). For the avoidance of doubt, the Selling Stockholder may not Transfer any shares of Company Capital Stock to the Proposed Transferee
unless the Proposed Transferee shall simultaneously purchase, in accordance with Tag-Along Terms, all of shares of Company Capital Stock to be disposed of by any Tagging Stockholders in accordance with this Article III. 
 (b) If any Tagging Stockholder exercises its rights under this Article III, the closing of the purchase of the Company Capital Stock with respect to
which such rights have been exercised will take place concurrently with the closing of the sale of the Selling Stockholder’s Company Capital Stock to the Proposed Transferee. If by the end of ninety (90) days following the date of delivery
of the Tag-Along Opportunity Notice (or, following the delivery of the last Amended Tag-Along Opportunity Notice, if applicable), the Selling Stockholder and the Proposed Transferee have not completed the Proposed Sale, each Tagging Stockholder
shall be released from its obligations under this Article III, and the Tag-Along Exercise Notices shall be null and void, and it shall be necessary for the terms of this Article III to be separately complied with in order to consummate such Proposed
Sale pursuant to this Article III. 
 SECTION 3.04. Tag-Along Power of Attorney. Upon delivering a Tag Along Exercise Notice, each
Tagging Stockholder will, if requested by the Selling Stockholder, execute and deliver a power of attorney in form and substance reasonably satisfactory to the Selling Stockholder with respect to the shares of Company Capital Stock that are to be
sold by such Tagging Stockholder pursuant hereto (a “Tag-Along Power of Attorney”). The Tag-Along Power of Attorney will provide, among other things, that each such Tagging Stockholder will irrevocably appoint said attorney-in-fact
as its agent and attorney-in-fact with full power and authority to act under the Tag-Along Power of Attorney on its behalf with respect to (and subject to the terms and conditions of) the matters specified in this Article III. 
 ARTICLE IV. 
 DRAG-ALONG RIGHTS

 SECTION 4.01. Drag-Along Rights. If WCAS IX (the “Dragging Stockholder”), the Company or USON receives an
offer from a Person who is not an Affiliate of the Company or WCAS IX (a “Third Party”) to purchase or exchange (by merger, consolidation or otherwise) (x) at least a majority of the shares of Company Common Stock then
outstanding and/or at least a majority of the shares of Company Preferred Stock then outstanding or (y) all or substantially all of the assets of the Company and its subsidiaries taken as a whole, and WCAS IX wishes to accept such offer (or
WCAS IX wishes that the Company or USON accept such offer), then each Stockholder other than WCAS IX (the “Drag-Along Stockholders”) hereby agrees that, if requested by the Dragging Stockholder, such Stockholder will (A) waive
any appraisal rights that it would otherwise have in respect of such transaction, and/or (B) Transfer to such Third Party, subject to the other provisions of this Article IV, on the terms of the offer so accepted by the Dragging Stockholder,
including time of payment, form and choice of consideration and adjustments to purchase price, (i) the number of shares of Company Preferred Stock equal to the number of shares of Company Preferred Stock owned by such Stockholder multiplied by
the percentage of the then outstanding shares of Company Preferred Stock to which the Third Party offer is applicable, if any, and (ii) the number of shares of Company Common Stock equal to the 

  

 11 

 
number of outstanding shares of Company Common Stock owned by such Stockholder multiplied by the percentage of the then outstanding shares of Company Common
Stock to which the Third Party offer is applicable, if any. 
 SECTION 4.02. Exercise of Drag-Along Rights; Notices; Certain Conditions of
Drag-Along Sales. (a) The Dragging Stockholder will give notice (the “Drag-Along Notice”) to the Drag-Along Stockholders of any proposed Transfer giving rise to the rights of the Dragging Stockholder set forth in
Section 4.01 (a “Drag-Along Sale”) within five (5) Business Days after the Dragging Stockholder’s acceptance of the offer referred to in Section 4.01 and, in any event, not less than fifteen (15) Business
Days prior to the proposed closing date for such Drag-Along Sale. The Drag-Along Notice will set forth the number and type of shares of Company Capital Stock proposed to be so Transferred, the name of the proposed transferee or acquiring Person, the
proposed amount and form of consideration, the number and type of shares of Company Capital Stock sought and the other terms and conditions of the offer. 
 (b) If any holders of Company Capital Stock are given an option as to the form and amount of consideration to be received, all holders of such class of Company Capital Stock shall be given the same option. Each
Drag-Along Stockholder (x) shall agree to the same covenants as the Dragging Stockholder agrees to in connection with the Drag-Along Sale, (y) shall be obligated to join on a pro rata (and several) basis (based on the proceeds
received by each such Drag-Along Stockholder in connection with the Drag-Along Sale) in any indemnification that the Dragging Stockholder agrees to provide in connection with the Drag-Along Sale (other than in connection with obligations that relate
to a particular Stockholder such as representations and warranties concerning itself for which each Stockholder shall agree to be solely responsible, and provided further that the liability for any such pro rata indemnification obligations shall not
exceed the total consideration received by such Stockholder for such shares) and (z) shall make such representations and warranties concerning itself and the shares of Company Capital Stock to be sold by it in connection with such Drag-Along
Sale as the Dragging Stockholder makes with respect to itself and its shares. 
 (c) Each Drag-Along Stockholder will be responsible for
funding its proportionate share of any adjustment in purchase price or escrow arrangements in connection with the Drag-Along Sale and for its proportionate share of any withdrawals from any such escrow, including any such withdrawals that are made
with respect to claims arising out of agreements, covenants, representations, warranties or other provisions relating to the Drag-Along Sale. 
 (d) Each Drag-Along Stockholder will be responsible for its proportionate share of the Costs of the Drag-Along Sale to the extent not paid or reimbursed by the Company, the Third Party or another Person (other than the Dragging
Stockholder); provided, that the liability for such Costs shall not exceed the total consideration received by such Drag-Along Stockholder for its Company Equity Securities in respect of such Drag-Along Sale. The Dragging Stockholder shall be
entitled to estimate each Drag-Along Stockholder’s proportionate share of such Costs and to withhold such amounts from payments to be made to each Drag-Along Stockholder at the time of closing of the Drag-Along Sale; provided that
(i) such estimate shall not preclude the Dragging Stockholder from recovering additional amounts from the Drag-Along Stockholders in respect of each Drag-Along Stockholder’s proportionate share of such 

  

 12 

 
Costs and (ii) the Dragging Stockholder shall reimburse each Drag-Along Stockholder to the extent actual amounts are ultimately less than the estimated
amounts or any such amounts are paid by the Company, the Third Party or another Person (other than the Dragging Stockholder). 
 SECTION
4.03. Closing of Drag-Along Sale. (a) At the closing of such Drag-Along Sale, each of the Drag-Along Stockholders shall deliver certificates evidencing the Company Equity Securities then held by it and to be sold or cancelled in
connection with such sale, duly endorsed for transfer or accompanied by stock powers executed in blank, against payment of the purchase price therefor by wire transfer to the account or accounts specified by such Drag-Along Stockholder. 

(b) If the Drag-Along Sale is not consummated within 120 days from the date of the Drag-Along Notice, the Dragging Stockholder must deliver another
Drag-Along Notice in order to exercise its rights under this Article IV with respect to such Drag-Along Sale. 
 SECTION 4.04. Custody
Agreement and Power of Attorney. Upon receiving a Drag-Along Notice, each Drag-Along Stockholder will, if requested by the Dragging Stockholder, execute and deliver a custody agreement and power of attorney in form and substance reasonably
satisfactory to the Dragging Stockholder with respect to the shares of Company Capital Stock that are to be sold by such Drag-Along Stockholder pursuant hereto and with respect to any other Company Equity Securities subject to this Article IV in
respect of such Drag-Along Sale (a “Drag-Along Custody Agreement and Power of Attorney”). The Drag-Along Custody Agreement and Power of Attorney will provide, among other things, that each such Drag-Along Stockholder will deliver to
and deposit in custody with the custodian and attorney-in-fact named therein a certificate or certificates representing such shares of Company Capital Stock (each duly endorsed in blank by the registered owner or owners thereof) and irrevocably
appoint said custodian and attorney-in-fact as its agent and attorney-in-fact with full power and authority to act under the Drag-Along Custody Agreement and Power of Attorney on its behalf with respect to (and subject to the terms and conditions
of) the matters specified in this Article IV. 
 ARTICLE V. 
 PREEMPTIVE RIGHTS 
 SECTION 5.01. Grant of Preemptive Rights. The Company hereby grants to
each Qualified Stockholder the right to purchase such Qualified Stockholder’s Proportionate Percentage (as hereinafter defined) of any Company Equity Securities to be issued in any future Eligible Issuance (as hereinafter defined). For the
purposes of this Article V, the following terms shall have the meanings set forth below: 
 “Proportionate
Percentage” means, with respect to any Qualified Stockholder as of any date, the result (expressed as a percentage) obtained by dividing (i) the number of shares of Company Common Stock owned by such Qualified Stockholder as of such
date on a Fully Diluted Basis by (ii) the total number of shares of Company Common Stock outstanding as of such date on a Fully Diluted Basis. 
  

 13 

 “Eligible Issuance” means the issuance by the Company to any Person or
Persons (including any of the Stockholders) for cash, cash equivalents, property or indebtedness of any Company Equity Securities, other than an issuance by the Company: 
 (i) of shares of Company Common Stock or options to purchase shares of Company Common Stock in connection with or pursuant to (x) a
Company Stock Plan or (y) any offering to physicians affiliated with the Company; 
 (ii) of Company Equity Securities in
connection with a bona fide business acquisition, reorganization or recapitalization of or by the Company or any Subsidiary thereof, whether by merger, consolidation, sale of assets, sale or exchange or otherwise; 
 (iii) of Company Equity Securities to any Person with which the Company has business relationships provided that such issuances are for
other than primarily equity financing purposes; 
 (iv) of Company Equity Securities upon the exercise, exchange or conversion
of Options or Convertible Securities; 
 (v) of Company Equity Securities to a lender (including any Stockholder or any of
their Designated Affiliates) in connection with a debt financing or the amendment of any debt financing arrangements; or 
 (vi) of Company Equity Securities in a Public Offering. 
 SECTION 5.02. Notice of Eligible Issuance. The Company shall,
before issuing any Company Equity Securities in an Eligible Issuance, give written notice thereof to each Qualified Stockholder. Such notice shall specify the Company Equity Securities the Company proposes to issue, the proposed date of issuance,
the consideration that the Company intends to receive therefor and all other material terms and conditions of such proposed issuance. For a period of ten (10) days following the date of receipt of such notice, each Qualified Stockholder shall
be entitled, by written notice to the Company, to elect to purchase all or any part of such Qualified Stockholder’s Proportionate Percentage of the Company Equity Securities being sold in the Eligible Issuance; provided, that if two or
more securities shall be proposed to be sold as a “unit” in an Eligible Issuance, any such election must relate to such unit of securities. To the extent that elections pursuant to this Section 5.02 shall not be made with respect to
any Company Equity Securities included in an Eligible Issuance within such ten (10) day period, then the Company may issue such Company Equity Securities, but only for consideration not less than, and otherwise on terms no less favorable to the
Company than, those set forth in the Company’s notice and only within ninety (90) days after the end of such ten (10) day period. In the event that any such offer is accepted by one or more Qualified Stockholder or Qualified
Stockholders, the Company shall sell to such Qualified Stockholder or Qualified Stockholders, and such Qualified Stockholder or Qualified Stockholders shall purchase from the Company, for the consideration and on the terms set forth in the notice as
aforesaid, the securities that such Qualified Stockholder or Qualified Stockholders shall have elected to purchase and the Company 

  

 14 

 
may sell the balance, if any, of the Company Equity Securities it proposed to sell in such Eligible Issuance in accordance with the immediately preceding
sentence. Notwithstanding anything to the contrary contained above, if the Board shall have determined that it is in the best interests of the Company to proceed with an Eligible Issuance prior to providing the notices required by this Article V or
affording each of the Qualified Stockholders its preemptive rights in strict compliance with this Article V, the Company shall be permitted to first consummate such issuance (the buyer of such shares in such issuance is referred to herein as the
“Buyer”) and thereafter deliver such notices and afford the Qualified Stockholders an opportunity to exercise their preemptive rights hereunder so long as such notices are delivered and such preemptive rights offer is conducted as
soon as practicable thereafter and such offer is structured such that (i) each Qualified Stockholder shall have the right to buy at the same price and on the same terms as the Buyer and (ii) after giving effect to the exercise of its
preemptive rights in connection with such Eligible Issuance in full, such Qualified Stockholder shall hold the same Proportionate Percentage of Company Equity Securities that it held immediate prior to such Eligible Issuance. 
 ARTICLE VI. 
 INFORMATION RIGHTS

 SECTION 6.01. Information Rights. Unless the Company has timely filed periodic reports with the Securities and Exchange
Commission pursuant to the Exchange Act or any indenture or other agreement governing indebtedness of the Company, the Company shall provide to Morgan Stanley (so long as it is a Qualified Stockholder), each of its Permitted Transferees (so long as
such Permitted Transferee is a Qualified Stockholder) and each Schedule IV Purchaser, by electronic means or otherwise, (a) annual audited financial statements within 90 days of the end of the Company’s fiscal year, and (b) a
statement of operations within 45 days of the end of each of the Company’s first three fiscal quarters, each prepared in accordance with generally accepted accounting principles. Without limiting the foregoing, from and after the date hereof,
on reasonable prior written notice, the Company shall make its directors, officers, key employees, lawyers, accountants, agents and other consultants of the Company reasonably available to such Stockholders to discuss the business, results of
operations and other matters pertaining to the Company, it being understood and agreed that no Schedule IV Purchaser shall be permitted to exercise the rights granted pursuant to this sentence more than two (2) times in any fiscal year. In
addition, (i) the Company shall provide Morgan Stanley (so long as it is a Qualified Stockholder) and each of its Permitted Transferees (so long as such Permitted Transferee is a Qualified Stockholder) copies of all information delivered to the
Company’s stockholders or senior lenders and such other financial information that is distributed to the members of the Board; and (ii) Morgan Stanley (so long as it is a Qualified Stockholder), each of its Permitted Transferees (so long
as such Permitted Transferee is a Qualified Stockholder) and their respective representatives will have the right, upon reasonable prior written notice to the Company and only at times during normal business hours and which would not cause undue
disruption to the Company’s business or operations, to visit and inspect the Company’s properties and examine the corporate and financial records of the Company; provided, such Stockholder may not exercise the right set forth in
clause (ii) more than two (2) times in any fiscal year. Any and all information provided to any such Stockholder pursuant to the terms of this Article VI shall be subject to the agreements with respect to Confidential Information (as
hereinafter defined) set forth in Article VII. 
  

 15 

 ARTICLE VII. 
 CONFIDENTIALITY 
 SECTION 7.01. Confidential Information. (a) Each Stockholder agrees
that it will not use at any time any Confidential Information of which any such Stockholder is or becomes aware except in connection with determining the interest of the Stockholder in entering into a transaction with the Company. 
 (b) Each Stockholder further agrees that the Confidential Information will be kept strictly confidential and will not be disclosed by it or its
Representatives (as defined below), except (i) as required by applicable law, rule regulation or legal process or in response to any inquiry from a regulatory authority having jurisdiction over such Stockholder, and only after compliance with
Section 7.01(c) and (ii) that it may disclose the Confidential Information or portions thereof to those of its officers, employees, members, managers, directors, advisors, financing sources, bona fide potential transferees and other agents
and representatives (the persons to whom such disclosure is permissible being “Representatives”) who need to know such information in connection with the investment by the Stockholder in the Company; provided that such
Representatives (x) are informed of the confidential and proprietary nature of the Confidential Information and (y) agree to maintain such confidentiality in accordance with the provisions of this Article VII. Each Stockholder agrees to be
responsible for any breach of this Article VII by its Representatives (it being understood that such responsibility shall be in addition to and not by way of limitation of any right or remedy the Company may have against such Representatives with
respect to any such breach). 
 (c) If any Stockholder or Representative thereof becomes legally compelled (including by deposition,
interrogatory, request for documents, subpoena, civil investigative demand, regulatory agency or stock exchange rule or similar process) to disclose any of the Confidential Information, such Stockholder or Representative shall provide the Company
with prompt and, if legally permissible, prior written notice of such requirement to disclose such Confidential Information. Upon receipt of such notice, the Company may seek a protective order or other appropriate remedy. If such protective order
or other remedy is not obtained, such Stockholder and its Representatives shall disclose only that portion of the Confidential Information which is legally required to be disclosed and shall take all reasonable steps to preserve the confidentiality
of the Confidential Information. In addition, neither such Stockholder nor its Representative will oppose any action (and such Stockholder and its Representatives will, if and to the extent requested by the Company and legally permissible to do so,
cooperate with and assist the Company, at the Company’s expense and on a reasonable basis, in any reasonable action) by the Company to obtain an appropriate protective order or other reliable assurance that confidential treatment will be
accorded the Confidential Information. 
 (d) As used herein, “Confidential Information” means oral and written information
concerning the Company and its subsidiaries furnished to any Stockholder or Representative thereof by or on behalf of the Company (irrespective of the form of communication and whether such information is so furnished before, on or after the date
hereof), and all analyses, compilations, data, studies, notes, interpretations, memoranda or other documents prepared by any Stockholder or any Representative thereof containing or based in 

  

 16 

 
whole or in part on any such furnished information. The term “Confidential Information” does not, with respect to any Stockholder, include any
information which (i) at the time of disclosure or thereafter is generally available to the public (other than as a result of a disclosure directly or indirectly by such Stockholder or its Representative in violation hereof), (ii) is or
becomes available to such Stockholder or its Representatives on a non-confidential basis from a source other than the Company or its advisors provided that such source was not known by such Stockholder or its Representatives to be prohibited from
disclosing such information to such Stockholder by a legal, contractual or fiduciary obligation, (iii) with respect to any Stockholder that is an investment partnership or government pension plan, the identity of the Company or the amount
invested in Company Capital Stock by such Stockholder, (iv) was already in the possession of Stockholder or its Representatives prior to receiving such information from the Company or its advisors, or (v) was developed independently by
Stockholder or its Representatives without use of the Confidential Information. 
 (e) The provisions of this Article VII shall terminate and
be of no further force or effect on the earlier to occur of (i) the termination of this Agreement as set forth in Section 10.07 herein or and (ii) the date which is one year from the date such Stockholder no longer holds any Company
Equity Securities. 
 ARTICLE VIII. 
 VOTING AGREEMENT 
 SECTION 8.01. Election of Directors. (a) Each Stockholder hereby agrees to cast all votes to
which such Stockholder is entitled in respect of his, her or its shares of Company Capital Stock, whether at any annual or special meeting, by written consent or otherwise, to: 
 (i) fix the number of members of the Board at a number specified from time to time by WCAS IX, which number shall be at least two;

 (ii) for so long as Morgan Stanley or any of its Permitted Transferees shall hold any shares of Company Capital Stock,
elect as members of the Board one (1) individual designated by Morgan Stanley or its Permitted Transferees and reasonably acceptable to WCAS IX (such approval not to be unreasonably withheld, delayed or conditioned); 
 (iii) elect as members of the Board such number of individuals designated by WCAS IX equal to the authorized number of directors less the
one director designated pursuant to clause (ii) above; and 
 (iv) remove from the Board (with or without cause) any
director elected in accordance with this Section 8.01 upon the written request of the Stockholder that designated and continues to have the right to designate such director (it being understood that no Stockholder shall vote for or consent to
and the Company shall not take any actions to effect any other removal (with or without cause) of a director elected pursuant to this Section 8.01 without the written consent of the Stockholder that designated and continues to have the right to
designate such director). 
  

 17 

 (b) If, as a result of death, disability, retirement, resignation or removal (with or without cause),
there shall exist or occur any vacancy of the Board: 
 (i) the Person entitled to designate or nominate such director whose
death, disability, retirement or removal resulted in such vacancy may designate another individual (the “Nominee”) to fill such capacity and serve as a director of the Company; and 
 (ii) each Stockholder then entitled to vote for the election of the Nominee as a director of the Company agrees that it will vote its
shares of Company Capital Stock in order to ensure that the Nominee be elected to the Board. 
 (c) Each Stockholder will vote such
Stockholder’s shares of Company Capital Stock or execute written consents, as the case may be, and the Company and each Stockholder will take all other actions as may be reasonably necessary or appropriate (including, if applicable, calling or
causing the Company to call a special meeting of its stockholders), to carry out the purposes and intent of this Section 8.01. 
 SECTION 8.02. Special Protective Provisions. At any time when shares of Series A-1 Preferred Stock are outstanding, in addition to any other vote required by law, without the prior written consent of the holders of not less than a
majority of the outstanding shares of Series A-1 Preferred Stock held by Morgan Stanley and its Permitted Transferees (which consent will not be unreasonably withheld, delayed or conditioned), the Company will not and will not permit any Subsidiary
to: 
 (i) increase the total number of shares of Series A-1 Preferred Stock authorized to be issued by the Company
Certificate; 
 (ii) create, obligate itself to create, authorize or issue any new class or series of Company Equity
Securities having preference over the Series A-1 Preferred Stock with respect to payment of dividends, redemption payments or payment upon liquidation, dissolution or winding-up of the Company; 
 (iii) enter into any transaction that would result in a Change of Control (as defined in the Company Certificate), other than (A) any
such transaction that is permitted in accordance with Articles III, IV or V of this Agreement or (B) any such transaction pursuant to which the holders of Company Preferred Stock receive the same consideration per share (other than differences
that may result from differences in the Accreted Value (as defined in the Company Certificate) of such shares) and all holders of Company Common Stock receive the same consideration per share; 
 (iv) authorize, declare or set aside or pay any dividend or other distribution to holders of Company Capital Stock, other than
(A) the one-time 

  

 18 

 
distribution to holders of Series A Preferred Stock and Common Stock on or about the date hereof and contemplated by the Stock Purchase Agreement,
(B) Regular Dividends (as defined in the Company Certificate) which are paid to all holders of Company Preferred Stock in accordance with paragraph 2 of the Company Certificate, (C) distributions made in accordance with paragraphs 3, 4 or
5 of the Company Certificate, or (D) dividends or other distributions which are made to all holders of Company Preferred Stock on a pro rata basis (subject to differences that may result from differences in the Accreted Value of such shares);

 (v) authorize or make any repurchase or redemption of any shares of Company Equity Securities, other than
(A) repurchases or redemptions in accordance with paragraphs 3 or 5 of the Company Certificate, (B) repurchases or redemptions in accordance with agreements with employees of the Company or any Subsidiary that are approved by the Board or
(C) other repurchases or redemptions in which all holders of Company Preferred Stock have the right to participate on a pro rata basis (subject to differences that may result from differences in the Accreted Value of such shares); 

(vi) enter into any material transaction with any Affiliate of the Company, other than (A) any such transaction permitted in
accordance with Article V of this Agreement, (B) any such transaction that is permitted by the provisions of the Indenture, dated March 29, 2005, between the Company and LaSalle Bank National Association, as Trustee, relating to the
Company’s outstanding senior floating rate notes due 2015 or (C) any such transaction with Morgan Stanley or any Affiliate of Morgan Stanley that is approved by the Board (for avoidance of doubt, any Excluded Transaction or Proposed Sale
permitted in accordance with Article III and any Drag-Along Sale to a Third Party permitted in accordance with Article IV shall not be considered a material transaction with an Affiliate of the Company for purposes of this Section 8.02(vi));
and 
 (vii) consummate any Public Offering that is not a Qualified Public Offering or cause USON to consummate the sale of
shares of common stock of USON to the public pursuant to an effective registration statement (other than a registration statement on Form S-4, Form S-8 or any similar or successor form). 
 ARTICLE IX. 
 REPRESENTATIONS AND WARRANTIES 
 SECTION 9.01. Representations and Warranties by the Stockholders. Each Stockholder, severally and not jointly, represents and warrants to the
Company and the other Stockholders as follows: 
 (a) The execution, delivery and performance of this Agreement by such Stockholder will not
violate any provision of applicable law, any order of any court or other agency of government, the certificate or articles of incorporation, bylaws, operating agreement, 

  

 19 

 
partnership agreement or other organizational documents of such Stockholder or any provision of any indenture, agreement or other instrument to which such
Stockholder or any of such Stockholder’s properties or assets is bound, or conflict with, result in a breach of or constitute (with due notice or lapse of time or both) a default under any such indenture, agreement or other instrument.

 (b) This Agreement has been duly executed and delivered by such Stockholder, and, when executed by the other parties hereto, will
constitute the legal, valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms. 
 SECTION 9.02. Representations and Warranties by the Company. The Company represents and warrants to each Stockholder as follows: 
 (a) The execution, delivery and performance of this Agreement by the Company will not violate any provision of applicable law, any order of any court or other agency of government, the Company Certificate or the Company’s Bylaws or any
provision of any indenture, agreement or other instrument to which the Company or any of its properties or assets is bound, or conflict with, result in a breach of or constitute (with due notice or lapse of time or both) a default under any such
indenture, agreement or other instrument. 
 (b) This Agreement has been duly executed and delivered by the Company, and, when executed by
the other parties hereto, will constitute the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms. 
 ARTICLE X. 
 MISCELLANEOUS 
 SECTION 10.01. Severability. In the event that any one or more of the provisions contained in this Agreement or in any other instrument referred
to herein shall, for any reason, be held to be invalid, illegal or unenforceable, such illegality, invalidity or unenforceability shall not affect any other provisions of this Agreement. 
 SECTION 10.02. Benefits of Agreement. Nothing expressed by or mentioned in this Agreement is intended or shall be construed to give any Person
other than the parties hereto and their respective successors and permitted assigns any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained, this Agreement and all conditions and
provisions hereof being intended to be and being for the sole and exclusive benefit of the parties hereto and their respective successors and permitted assigns. Notwithstanding anything in this Section 10.02 to the contrary, subject to
compliance with the terms of this Agreement, each Stockholder shall have the right to assign its rights hereunder in whole or in part to any transferee of the Company Equity Securities held by such Stockholder in compliance with this Agreement
(including Section 2.02) . Except as expressly permitted hereby, each party’s rights and obligations under this Agreement shall not be subject to assignment or delegation by any party hereto, and any attempted assignment or delegation in
violation hereof shall be null and void ab initio. 
  

 20 

 SECTION 10.03. Notice of Transfer. To the extent that any Stockholder shall Transfer any Company
Equity Securities, notice of which Transfer is not otherwise required to be delivered to the Stockholders hereunder, such Stockholder shall, within three (3) days following consummation of such Transfer, deliver notice thereof to the Company
and WCAS IX. 
 SECTION 10.04. Notices. Any notice or communication required or permitted hereunder shall be in writing and shall be
delivered personally, delivered by nationally recognized overnight courier service, sent by certified or registered mail, postage prepaid, or sent by facsimile (subject to confirmation by return facsimile of such facsimile transmission). Any such
notice or communication shall be deemed to have been received (i) when delivered, if personally delivered, (ii) one (1) Business Day after it is deposited with a nationally recognized overnight courier service, if sent by nationally
recognized overnight courier service, (iii) the day of sending, if sent by facsimile prior to 5:00 p.m. (EST) on any Business Day or the next succeeding Business Day if sent by facsimile after 5:00 p.m. (EST) on any Business Day or on any day
other than a Business Day or (iv) five Business Days after the date of mailing, if mailed by certified or registered mail, postage prepaid, in each case, to the following address or facsimile number, or to such other address or addresses or
facsimile number or numbers as such party may subsequently designate to the other parties by notice given hereunder: 
 if to the Company, to
it at: 
 16825 Northchase Drive 
 Houston, Texas 77060 
 Facsimile: (832) 601-6688 
 Attention: Chief Executive Officer 
 with a copy to: 
 Welsh, Carson, Anderson & Stowe IX, L.P. 
 320 Park Avenue, Suite 2500 
 New York, New York 10022 
 Attention: D. Scott Mackesy 
 Facsimile: (212) 893-9566 
 with an additional copy to: 
 Ropes &
Gray LLP 
 45 Rockefeller Plaza 
 New York, New York 10111 
 Attention: Othon A. Prounis, Esq. 
 Facsimile: (212) 841-5725 
 if to any
Stockholder, to such Stockholder at the address set forth opposite such Stockholder’s name on Schedule I hereto. 
 SECTION
10.05. Entire Agreement; Modification. This Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes 

  

 21 

 
all prior agreements and understandings, both oral and written, among the parties with respect to the subject matter hereof. This Agreement may not be
amended, modified or waived except by an instrument in writing signed by the Company, WCAS IX and Stockholders other than WCAS IX (the “Other Stockholders”) holding not less than a majority of the shares of Company Common Stock held
by the Other Stockholders on a Fully Diluted Basis; provided, that, (i) no provision of this Agreement may be amended, modified or waived in a manner materially adverse to any Other Stockholder (in its capacity as a Stockholder
hereunder) if such amendment, modification or waiver adversely affects such Other Stockholder disproportionately relative to the other Other Stockholders (disregarding for such purposes differences resulting solely from the amount of Company Equity
Securities held by the Other Stockholders) except with the written consent of such adversely and disproportionately effected Other Stockholder, (ii) no provision of Article III may be amended, modified or waived in any manner that would
diminish the rights of any Schedule IV Purchaser unless such Schedule IV Purchaser consents in writing to such amendments, modifications or waivers (such consent not to be unreasonably withheld or delayed) and (iii) no provision of this
Agreement may be amended, modified or waived in any manner that would diminish the rights of Morgan Stanley or any of its Permitted Transferees unless the holders of a majority of the Company Equity Securities held by Morgan Stanley and its
Permitted Transferees consents in writing to such amendments, modifications or waivers (such consent not to be unreasonably withheld or delayed); provided, further, that, notwithstanding the foregoing, in accordance with Article II or
upon the written agreement of the Company and WCAS IX, additional Stockholders may be added to this Agreement (it being understood that any amendment of the provisions of this Agreement in connection with the addition of new Stockholders to this
Agreement does not require the prior written consent of the Schedule IV Purchasers or Morgan Stanley and its Permitted Transferees, as the case may be, so long as (i) in the case of the Schedule IV Purchasers, no provision of Article III is
amended in any manner that would diminish the rights of any Schedule IV Purchaser and (ii) in the case of the Morgan Stanley and its Permitted Transferees, no provision of this Agreement is amended in a manner adverse to any of Morgan Stanley
or its Permitted Transferees). Except as otherwise provided herein, any waiver of any provision of this Agreement must be in a writing signed by the party against whom enforcement of such waiver is sought. Notwithstanding anything to the contrary in
this Section 10.05, the Company and any Stockholder or Stockholders may agree among themselves to terms and conditions that are different from the terms and conditions set forth in this Agreement. 
 SECTION 10.06. Covenants Bind Successors and Assigns. All the covenants, stipulations, promises and agreements in this Agreement contained by or
on behalf of any party shall bind its successors and permitted assigns, whether so expressed or not. 
 SECTION 10.07. Duration of
Agreement. This Agreement (other than the provisions of Section 2.03 and Article VII which shall survive the termination of this Agreement) shall terminate upon the earliest to occur of (x) a Qualified Public Offering or (y) a
Qualified Merger. This Agreement shall terminate with respect to any Stockholder when such Stockholder ceases to be a holder of any shares of Company Preferred Stock or Company Common Stock. 
  

 22 

 SECTION 10.08. Counterparts. This Agreement may be executed in any number of counterparts, and
each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. 
 SECTION 10.09. Changes in Company Common Stock. If, and as often as, there are any changes in Company Common Stock by way of stock split, stock dividend, combination or reclassification, or through merger, consolidation,
reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof as may be required so that the rights and privileges granted hereby shall continue with respect to the Company Common Stock as
so changed. 
 SECTION 10.10. Specific Performance. Each party hereto agrees that a remedy at law for any breach or threatened breach
by such party of this Agreement would be inadequate and therefore agrees that any other party hereto shall be entitled to pursue specific performance of this Agreement in addition to any other available rights and remedies in case of any such breach
or threatened breach. 
 SECTION 10.11. Governing Law. This Agreement, and all claims arising hereunder or relating hereto,
shall be governed and construed and enforced in accordance with the laws of the State of New York. 
 SECTION 10.12. Waiver Of Jury
Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 [SIGNATURE PAGES FOLLOW] 
  

 23 

 IN WITNESS WHEREOF, each of the parties hereto has duly executed and delivered this Stockholders
Agreement as of the date first written above. 
 THE COMPANY: 
  

			
	US ONCOLOGY HOLDINGS, INC.
		
	By:	 	  
	Name:	 	
	Title:	 	

 WCAS IX: 
  

			
	 WELSH, CARSON, ANDERSON &
STOWE IX, L.P.

		
	By:	 	WCAS IX Associates LLC, its General Partner
		
	By:	 	  
	Name:	 	
	Title:	 	

 MORGAN STANLEY: 
  

			
	 MORGAN STANLEY STRATEGIC
INVESTMENTS, INC.

		
	By:	 	  
	Name:	 	
	Title:	 	

 OTHER STOCKHOLDERS: 
  

			
	 WCAS MANAGEMENT CORPORATION

		
	By:	 	  
	Name:	 	
	Title:	 	
	
	 Russell L. Carson
 Bruce K.
Anderson
 Thomas E. McInerney
 Robert A. Minicucci
 Anthony J. de Nicola
 Paul B. Queally
 D. Scott Mackesy
 D. Scott Mackesy
– IRA
Charles Schwab & Co., Inc. Custodian
 Sanjay Swani
 John D. Clark – IRA
Charles Schwab & Co., Inc. Custodian
 John D. Clark
 James R. Matthews – IRA
Charles Schwab & Co., Inc. Custodian
 Jonathan M. Rather – IRA
Charles Schwab & Co., Inc. Custodian
 Sean M. Traynor
 John Almeida
 Rona Drogy
 Dave Mintz
 Clinton Biondo
 Ankar Kumar
 Michael E. Donovan
 Brian Regan
 Eric J. Lee

		
	By:	 	  
	Name:	 	Jonathan M. Rather
	Title:	 	Attorney-in-Fact

			
	 THE PATRICK WELSH 2004
IRREVOCABLE TRUST

		
	By:	 	  
	Name:	 	
	Title:	 	

	
	
	   
	R. Dale Ross
	
	   
	Lloyd K. Everson, M.D.
	
	   
	Phillip H. Watts
	
	   
	Bruce D. Broussard
	
	   
	George D. Morgan
	
	   
	Leo E. Sands
	
	   
	Atul Dhir, M.B.B.S., D. Phil

			
	ROSS RESOURCES LIMITED
		
	By:	 	  
	Name:	 	
	Title:	 	

 Schedule I to Amended and Restated Stockholders Agreement 
  

			
	 Stockholders
	  	 Address for Notices

	 Welsh, Carson, Anderson & Stowe IX, L.P.
 WCAS
Management Corporation
 Russell L. Carson
 Bruce K.
Anderson
 The Patrick Welsh 2004 Irrevocable Trust
 Thomas E.
McInerney
 Robert A. Minicucci
 Anthony J. de Nicola

Paul B. Queally
 D. Scott Mackesy
 Sanjay Swani
 John D. Clark
 IRA f/b/o John D. Clark
 IRA f/b/o D. Scott Mackesy
 IRA f/b/o James R. Matthews
 IRA f/b/o Jonathan M. Rather
 Sean M. Traynor
 John Almedia, Jr.
 Stacey Bellet*
 Suzanne Bellet Price*
 Rona Drogy
 David Mintz
 Clinton M. Biondo
 Ankur Kumar
 Michael E. Donovan
 Brian T. Regan
 Eric J. Lee
 Jill A. Hanau
	  	 c/o Welsh, Carson, Anderson & Stowe
 320 Park Avenue,
Suite 2500
 New York, New York 10022
 Attention: D. Scott
Mackesy
 Facsimile: (212) 893-9566

	*	Additional copy to: 

 125 East 72nd Street 
 Apt. 11-D 
 New York, NY 10021 
 Attention: David F. Bellet 

			
		
	 Robert A. Ortenzio
 Rocco A. Ortenzio
	  	 c/o Select Capital Corporation
 4718 Old Gettysburg Road,
Suite 405
 Mechanicsburg, PA 17055
 Attention: Robert
Nause
 Facsimile: (717) 972-1080

			
	 Stockholders
	  	 Address for Notices

	 Melkus Partners
 Melkus Family Foundation
 The Lauren Evelyn Melkus Trust
 Lauren Melkus
	  	 c/o Kenneth J. Melkus
 102 Woodmont Blvd., Suite
110
 Nashville, TN 37203
 Facsimile: (615)
383-0104

		
	Joelle M. Kayden	  	 c/o Accolade Partners, L.P.
 7900 Westpark Drive, Suite
T-602
 McLean, VA 22102
 Facsimile: (703)
749-7800

		
	 Weigers & Co. LLC
 Betsy Weigers 2002 Unit
Trust
 George A. Weigers 2001 Unit Trust
	  	 c/o Weigers Capital Management, LLC
 55 Madison Street,
Suite 680
 Denver, CO 80206

		
	Kyle M. Fink, M.D.	  	 PBM 391
 0105 Edwards Village Blvd., C104
 Edwards, CO 81632

		
	Texas Oncology, P.A.	  	 c/o R. Steven Paulson, M.D.
 12221 Merit Drive, Suite
500
 Dallas, TX 75251

		
	 R. Dale Ross
 Lloyd K. Everson, M.D.
 Phillip H. Watts
 Bruce D. Broussard
 George D. Morgan
 Leo E. Sands
 Atul Dhir, M.B.B.S., D. Phil
 Ross Resources Limited
 Richard J. Hall
	  	 c/o US Oncology, Inc.
 16825 Northchase Drive

Houston, TX 77060
 Attention: R. Dale Ross
 Facsimile: (832) 601-6688

			
	 Stockholders
	  	 Address for Notices

	Schedule IV Purchasers:	  	
		
	California State Teachers’ Retirement System	  	 7667 Folsom Boulevard, Suite 250
 Sacramento, CA
95826
 Attention: Real Desrochers and Seth Hall
 Facsimile: (916)
229 3790

		
	Gunners Investment Pte Ltd.	  	 c/o GIC Special Investments Pte Ltd.
 255 Shoreline
Drive, Suite 600
 Redwood City, CA 94065
 Attention: Andrew
Kwee
 Facsimile: (650) 802-1213

		
	Abu Dhabi Investment Authority	  	 P.O. Box 3600
 Corniche Street
 Abu Dhabi
 United Arab Emirates
 Attention: Abubaker Al Khouri
 Facsimile: (971 2)
626-4616

		
	A.S.F. Co-Investment Partners II, L.P.	  	 c/o IBM Retirement Funds
 3001 Summer Street, MD
49
 Stamford, CT 06905
 Attention: Betty Sheets
 Facsimile: (203) 316-2190
  
 With a copy to:
  
 c/o Portfolio Advisors, LLC

9 Old Kings Highway South
 Darien, CT 06820
 Attention: Hugh Perloff
 Facsimile: (203) 662-0013Amended and Restated Registration Rights Agreement

 Exhibit 10.3 
 EXECUTION COPY 
 AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT 
 AMENDED and RESTATED REGISTRATION RIGHTS AGREEMENT,
dated as of December 21, 2006, among US ONCOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), WELSH, CARSON, ANDERSON & STOWE IX, L.P., a Delaware limited partnership (“WCAS”), MORGAN
STANLEY STRATEGIC INVESTMENTS, INC., a Delaware corporation (“Morgan Stanley”), and each of the other individuals and entities from time to time named on Schedule I hereto (together with WCAS and Morgan Stanley, and together
with their respective successors and assigns that become a party to this Agreement in accordance with the terms hereof, each an “Investor” and collectively, the “Investors”). 
 RECITALS 
 WHEREAS, the Company, WCAS
and certain of the Investors entered into the original Registration Rights Agreement, dated as of August 20, 2004 (the “Original Registration Rights Agreement”) in connection with the acquisition by such Investors of shares of
Participating Preferred Stock, par value $0.001 per share, of the Company (the “Series A Preferred Stock”), and the shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”); 
 WHEREAS, the Company and Morgan Stanley have entered into a Stock Purchase Agreement, dated as of December 21, 2006 (the “Stock Purchase
Agreement”), pursuant to which the Company has agreed to sell to Morgan Stanley shares of Series A-1 Participating Preferred Stock, par value $0.001 per share, of the Company (the “Series A-1 Preferred Stock” and together
with the Series A Preferred Stock, the “Participating Preferred Stock”) and shares of Common Stock; and 
 WHEREAS, in
connection with the investment contemplated by the Stock Purchase Agreement, the Company, WCAS and certain other Investors wish to amend and restate the Original Registration Rights Agreement in the manner set forth herein; 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 
 SECTION 1. Certain Definitions. For purposes of this Agreement, the following terms have the meanings set forth below: 
 “Commission” means the Securities and Exchange Commission, or any other federal agency at the time administering the Securities Act. 

 “Exchange Act” means the Securities Exchange Act of 1934, or any
successor federal statute, and the rules and regulations of the Commission thereunder, as the same may be amended from time to time. 
 “Initiating Investor” means, with respect to any Demand Registration, the Investor or Investors who initially deliver the Demand Request applicable to such Demand Registration. 
 “IPO Date” means the first date on which Common Stock shall have been sold by the Company in a Public Offering.

 “Public Offering” means the sale of shares of Common Stock to the public pursuant to an effective
registration statement (other than a registration statement on Form S-4 or S-8 or any successor form) filed under the Securities Act. 
 “Registrable Stock” means, at any time, (x) all shares of Common Stock now or hereafter held by the Investors, including all shares from time to time issued or issuable upon the conversion,
exercise or exchange of any securities directly or indirectly convertible into or exercisable or exchangeable for Common Stock (other than (i) options issued pursuant to any stock option plan, including the Company’s 2004 Equity Incentive
Plan, and (ii) shares of restricted stock (including shares of Common Stock issued pursuant to the Company’s 2004 Equity Incentive Plan) that will not have vested before the earliest anticipated effective date of the registration statement
for any proposed offering of such restricted stock pursuant to this Agreement), that are now or hereafter held by the Investors, including the Participating Preferred Stock (it being understood that, with respect to any determination hereunder of
the number of shares of Registrable Stock at any time held by one or more Investors, all such shares of Common Stock that are issuable upon any such conversion, exercise or exchange shall be deemed to have been issued at the time of such
determination) and (y) any shares of Common Stock issuable with respect to the foregoing by way of stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or
otherwise; provided, that, with respect to the Company’s initial Public Offering only, “Registrable Stock” shall mean, with respect to each Investor, only that number of shares of Common Stock issued or issuable upon the
related conversion, if any, of the shares of Participating Preferred Stock then held by such Investor at the time of such conversion (assuming for such purposes that the Conversion Constant (such term being used herein as defined in the
Company’s certificate of incorporation) at such time is zero (0). As to any particular Registrable Stock, such shares shall cease to be Registrable Stock (i) when a registration statement with respect to the sale of such shares shall have
been declared effective under the Securities Act and such shares shall have been disposed of in accordance with such registration statement, (ii) when such shares shall have been sold (other than in a privately negotiated sale) pursuant to Rule
144 (or any successor provision) under the Securities Act, (iii) when, with respect to the holder thereof, such shares can be sold pursuant to Rule 144 promulgated under the Securities Act within a three month period without any volume
limitation or (iv) when, with respect to the holder thereof, all such shares held by such holder become eligible for sale under Rule 144(k) of the Securities Act (or any similar or successor rule). 

 “Securities Act” means the Securities Act of 1933, or any successor
federal statute, and the rules and regulations of the Commission thereunder, as the same may be amended from time to time. 
 SECTION 2.
Registration Rights. 
 (a) Demand Registration Rights. Subject to Section 2(c) below, if the Company shall (i) at
any time on or after the date hereof, be requested by WCAS or (ii) at any time on or after the date which is one hundred and eighty (180) days after the IPO Date, be requested by Morgan Stanley (provided, however, that a
request by Morgan Stanley may be made under this Section 2(a) within such 180 day period and upon receipt of any such request, the Company shall take actions to prepare the Demand Registration for filing; provided, further,
however, that the Company shall not be obligated to file with the SEC such Demand Registration until a date which is 180 days after the IPO Date), in each case, in a writing that states the number of shares of Registrable Stock to be sold and
the intended method of disposition thereof (each such written request, a “Demand Request”), to effect a registration under the Securities Act of all or any portion of the Registrable Stock then held by the Investors, the Company
shall immediately notify in writing (each such notice, a “Demand Registration Notice”) each other Investor of such proposed registration and shall use its commercially reasonable efforts to register under the Securities Act (each
such registration, a “Demand Registration”), for public sale in accordance with the method of disposition specified in such Demand Request, the number of shares of Registrable Stock specified in such Demand Request (plus the number
of shares of Registrable Stock specified in any written request for registration of shares of Registrable Stock that is received from each other Investor receiving the Demand Registration Notice within 20 days after receipt by such other Investor of
such Demand Registration Notice). In addition, with the written consent of the Initiating Investor, the Company shall be entitled to include in any Demand Registration, for sale in accordance with the method of disposition specified by such
Investor, shares of Common Stock to be sold by the Company for its own account or for the account of other holders. In the event that the proposed method of disposition specified by the Initiating Investor shall be an underwritten public offering,
(i) the managing underwriter shall be selected by such Investor (which selection, in the case of Morgan Stanley, shall be subject to the approval of the Company, which approval shall not be unreasonably withheld, conditioned or delayed); and
(ii) the number of shares of Registrable Stock to be included in such an offering may be reduced if and to the extent that, in the good faith opinion of the managing underwriter of such offering, inclusion of all shares would adversely affect
the marketing (including the offering price) of the Registrable Stock to be sold, and, in the case of any such reduction, shares shall be included in such offering to the extent so permissible on the following basis: (A) first, all
Registrable Stock proposed to be included by the Investors shall be included (subject to pro rata reduction among the Investors seeking to include Registrable Stock in such offering based on the number of such shares of Registrable
Stock held by the Investors) and (B) second, to the extent provided above, Common Stock proposed to be included by the Company for the account of the Company or other stockholders of the Company shall be included. The Company shall
abandon any Demand Registration upon the request of the Initiating Investor and neither the Company nor such Investor shall have any liability to any Investor with respect to such abandonment. Notwithstanding anything else to the contrary contained
herein, (i) the Company shall not be required to effect more than two Demand Registrations at the request of WCAS or more than two Demand Registrations at the request of Morgan Stanley, in each case, under this Section 2(a) on 

 
Form S-1 or any successor thereto, and (ii) the Company shall not be required to effect a Demand Registration hereunder unless (x) in the case of a
registration on Form S-1 or any successor thereto, the reasonably anticipated aggregate net proceeds thereof (determined at the time of the giving of the Demand Request) exceed $25,000,000, or (y) in the case of a registration on Form S-3 or
any successor thereto, such Demand Registration relates to the registration of at least 1,000,000 shares of Registrable Stock (as adjusted for any stock splits, stock dividends, stock combinations and similar events occurring after the date hereof),
in each case, determined at the time of the giving of the Demand Request. Notwithstanding anything to the contrary herein, each of WCAS and Morgan Stanley shall have the right to make an unlimited number of Demand Requests on Form S-3 or any
successor thereto; provided, however, that the Company shall not be required to effect more than two Demand Registrations in any twelve-month period under this Section 2(a) on Form S-3 or any successor thereto. 
 (b) Short-Form Registration Qualification. From and after the IPO Date, the Company shall use its commercially reasonable efforts to qualify under
the provisions of the Securities Act, and thereafter, to continue to qualify at all times, for registration on Form S-3 or any successor thereto. In the event the Company fails to so qualify, the Company shall be required to effect Demand
Registrations on Form S-1 or any successor thereto to the same extent as the Company would be required to effect Demand Registrations on Form S-3 or any successor thereto. 
 (c) Certain Provisions Relating to Demand Registrations. In connection with a Demand Registration, the Company shall be obligated to effect such
Demand Registration in accordance with the following provisions: 
 (i) the obligations of the Company under Section 2(a)
above to effect a Demand Registration shall be deemed satisfied only when a registration statement covering all of the shares of Registrable Stock specified in the applicable Demand Request and in each notice delivered by any other Investor
requesting registration of Registrable Stock in response to the Demand Registration Notice for sale in accordance with the intended method of disposition specified by Initiating Investor in the Demand Request shall have become effective and remained
effective through the end of the period of distribution of the registration contemplated thereby (determined as provided in the last paragraph of Section 2(f)); provided, however, that in the case of the initial Demand Registration in
which the proposed method of disposition specified by the Initiating Investor is an underwritten public offering on Form S-1, the obligations of the Company under Section 2(a) shall nevertheless be deemed satisfied if the number of shares to be
included in the offering by the Initiating Investor is reduced by not more than 20% because in good faith opinion of the managing underwriter of such proposed offering inclusion of all shares requested by such Investor to be included in the offering
would adversely affect the marketing (including the offering price) of the Registrable Stock to be sold; and 
 (ii) Without
the consent of the Initiating Investor, which will not be unreasonably withheld, the Company will not effect any registration of its Common Stock, whether for its own account or that of other holders, from the date of receipt of a Demand Request in
which the proposed method of disposition specified by the Initiating 

 
Investor is an underwritten public offering until the completion of the period of distribution (determined as provided in the last paragraph of
Section 2(f)) of the Registrable Stock covered by the registration statement filed pursuant to such Demand Request. 
 (d) Piggyback
Registration Rights. If at any time the Company proposes to register any of its Common Stock or any other equity securities (or other securities convertible into equity securities) of the Company under the Securities Act for sale to the public,
whether for its own account or for the account of other security holders or both (other than a Demand Registration, or a registration on Form S-4 or Form S-8 promulgated under the Securities Act (or any successor forms thereto) or any other form not
available for registering the Registrable Stock for sale to the public), as soon as practicable prior to the filing of such registration statement with the Commission, it will give written notice of its intention to effect such registration (each
such notice a “Piggyback Notice”) to (i) if such proposed registration is being made in connection with the Company’s initial Public Offering, WCAS and Morgan Stanley and, unless WCAS and Morgan Stanley elect to waive
their rights under this Section 2(d) as provided below with respect to such registration within twenty business days of receiving its Piggyback Notice, to each other Investor or (ii) if such proposed registration is to occur after the IPO
Date, to each Investor. Upon the written request of any Investor, given within 20 days after the giving of the Piggyback Notice to all Investors, to register any of its Registrable Stock (which request shall state the number of shares of Registrable
Stock to be so registered and the intended method of disposition thereof), the Company will use its commercially reasonable efforts to cause the Registrable Stock, as to which registration shall have been so requested, to be included in the
securities to be covered by the registration statement proposed to be filed by the Company, all to the extent required to permit the sale or other disposition by such Investor of such Registrable Stock so registered; provided, that nothing
herein shall prevent the Company from abandoning or delaying such registration at any time; provided, however, that the expenses of such withdrawn registration shall be borne by the Company in accordance with Section 2(i) hereof.
Notwithstanding anything to the contrary contained herein, in connection with any registration statement to be filed prior to the IPO Date, if WCAS and Morgan Stanley elect to waive their rights under this Section 2(d) with respect to such
registration and the related initial Public Offering, such waiver shall be effective as a waiver of the rights of all Investors under this Section 2(d) with respect to such registration and offering. In the event that any registration referred
to in this Section 2(d) shall be, in whole or in part, an underwritten public offering, such Registrable Stock shall be included in the underwriting on the same terms and conditions as the shares otherwise being sold through underwriters under
such registration. The number of shares of Registrable Stock to be included in such an underwritten offering may be reduced if and to the extent that, in the good faith opinion of the managing underwriter of such offering, inclusion of all shares
would adversely affect the marketing (including the offering price) of the shares to be sold, and, in the case of any such reduction, shares shall be included in such offering to the extent so permissible on the following basis:
(A) first, all shares proposed to be included by the Company for the account of the Company shall be included, (B) second, all Registrable Stock proposed to be included by the Investors shall be included (subject to
pro rata reduction among the Investors seeking to include Registrable Stock in such offering based on the number of such shares of Registrable Stock held by the Investors), and (C) finally, Common Stock proposed to be
included by the Company for the account of other stockholders of the Company shall be included. 

 (e) Holdback Agreement. Notwithstanding anything to the contrary contained in this Agreement, with
respect to any underwritten Public Offering by the Company, upon request of the managing underwriter of such offering, each Investor shall refrain from selling or otherwise transferring Registrable Stock (other than pursuant to Section 2(a) or
2(d) above) during the period beginning no earlier than the tenth day preceding the effective date of the registration statement for such offering and continuing through (i) in the case of the Company’s initial Public Offering, the end of
the period of distribution of the registration contemplated thereby but such period not to exceed 180 days after the IPO Date or (ii) in case of any other Public Offering, the end of the period of distribution of the registration contemplated
thereby but such period not to exceed 90 days after the shares are first sold to the public in such offering and, if requested by any managing underwriter of such offering, to execute a customary lock-up agreement. The foregoing provisions of this
Section 2(e) shall only be applicable to each Investor if all other Persons with registration rights (whether or not pursuant to this Agreement) and all officers, directors and holders of more than 1% of the then outstanding Common Stock of the
Company enter into similar agreements. The provisions of this Section 2(e) shall terminate upon the earlier to occur of (i) the second anniversary of the IPO Date and (y) WCAS giving written notice of such termination to the Company
(a copy thereof to be promptly forwarded by the Company to the other Investors). 
 (f) Certain Registration Procedures. If and
whenever the Company is required by the provisions of this Section 2 to use its commercially reasonable efforts to effect the registration of Registrable Stock under the Securities Act, the Company will, as expeditiously as possible:

 (i) (x) prepare (and afford the Investors Counsel (as hereinafter defined) reasonable opportunity to review and comment
thereon) and file with the Commission a registration statement with respect to such securities (A) in case of a Demand Registration on Form S-1 or any successor thereto, no later than 120 calendar days after the date of the applicable Demand
Request and (B) in the case of a Demand Registration on Form S-3 or any successor thereto, no later than 45 calendar days after the applicable Demand Request, and (y) use its commercially reasonable efforts to cause such registration
statement to become effective (A) in case of a Demand Registration on Form S-1 or any successor thereto, no later than 150 calendar days after the date such registration statement is filed with the SEC and (B) in the case of a Demand
Registration on Form S-3 or any successor thereto, no later than 75 calendar days after the date such registration statement is filed with the SEC, and (z) use its commercially reasonable efforts to cause such registration statement to remain
effective (A) in the case of a Demand Registration on Form S-1 or any successor thereto, until the earlier of (1) the date on which all Registrable Stock registered pursuant to such registration statement shall have been sold to the public
and (2) the date which is 180 calendar days after the date on which such registration statement is declared effective by the SEC and (B) in the case of a Demand Registration on Form S-3 or any successor thereto, until the earlier of
(1) the second anniversary of the effective date of such registration statement and (2) the date on which all of the Registrable Stock requested to be registered by the Investors is no longer considered Registrable Stock; 

 (ii) prepare (and afford the Investors Counsel reasonable opportunity to review and
comment thereon) and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective through the end of period
of distribution contemplated thereby (determined as provided in the last paragraph of Section 2(f)) and comply with the provisions of the Securities Act with respect to the disposition of all Registrable Stock covered by such registration
statement in accordance with the selling Investors’ intended method of disposition set forth in such registration statement through the end of such period of distribution; 
 (iii) furnish to each selling Investor and to each underwriter such number of copies of the registration statement and the prospectus
included therein (including each preliminary prospectus) as such persons may reasonably request in order to facilitate the public sale or other disposition of the Registrable Stock covered by such registration statement; 
 (iv) use its commercially reasonable efforts to register or qualify the Registrable Stock covered by such registration statement under the
securities or blue sky laws of such jurisdictions as WCAS, any other Initiating Investor, the Investors Counsel or, in the case of an underwritten public offering, the managing underwriter, shall reasonably request; provided, that the Company
will not be required to (x) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 2(f)(iv), (y) subject itself to taxation in any such jurisdiction in which it
would not otherwise be subject to taxation but for this Section 2(f)(iv) or (z) consent to general service of process in any jurisdiction in which it would not otherwise be subject to general service of process but for this
Section 2(f)(iv); 
 (v) immediately notify each selling Investor under such registration statement and each underwriter,
at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus contained in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing (and upon receipt of any such notice, each selling
Investor agrees to suspend sales of Registrable Stock covered by such prospectus until such time as the Company notifies it that the prospectus (as supplemented or amended) no longer includes any untrue statement of a material fact or omits to state
any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing) and use its commercially reasonable efforts to promptly prepare and file with the SEC a
supplement or amendment to the registration statement or other appropriate filing with the SEC to correct such untrue statement or omission, and deliver a number of copies of such supplement or amendment to each Investor selling Registrable Stock
pursuant to such registration statement as such Investor may reasonably request; 
 (vi) use its commercially reasonable
efforts (if the offering is underwritten) to furnish, at the request of WCAS, any other Initiating Investor or the Investors Counsel, 

 
on the date that Registrable Stock is delivered to the underwriters for sale pursuant to such registration: (A) an opinion, dated such date, of counsel
representing the Company for the purposes of such registration, addressed to the underwriters and to each selling Investor, stating that such registration statement has become effective under the Securities Act and that (1) to the best
knowledge of such counsel, no stop order suspending the effectiveness thereof has been issued and no proceedings for that purpose have been instituted or are pending or contemplated under the Securities Act, (2) the registration statement, the
related prospectus, and each amendment or supplement thereof, comply as to form in all material respects with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder (except that such counsel need
express no opinion as to financial statements, the notes thereto, and the financial schedules and other financial and statistical data contained therein) and (3) to such other effects as may reasonably be requested by counsel for the
underwriters or by WCAS, any other Initiating Investor or the Investors Counsel, and (B) a letter dated such date from the independent public accountants retained by the Company, addressed to the underwriters, stating that they are independent
public accountants within the meaning of the Securities Act and that, in the opinion of such accountants, the financial statements of the Company included in the registration statement or the prospectus, or any amendment or supplement thereof,
comply as to form in all material respects with the applicable accounting requirements of the Securities Act, and such letter shall additionally cover such other financial matters (including information as to the period ending no more than five
business days prior to the date of such letter) with respect to the registration in respect of which such letter is being given as such underwriters, WCAS, any other Initiating Investor or the Investors Counsel may reasonably request; 
 (vii) make available for inspection by WCAS, any other Initiating Investor, any underwriter participating in any distribution pursuant to
such registration statement, the Investors Counsel and any accountant or other agent retained by one ore more of such parties, all financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s
officers, directors and employees to supply all information reasonably requested by WCAS, any other Initiating Investor, the Investors Counsel or any of such underwriters, attorneys, accountants or agents in connection with such registration
statement and permit WCAS, any other Initiating Investor, the Investors Counsel and such underwriters, attorneys, accountants or agents to participate in the preparation of such registration statement; 
 (viii) use its commercially reasonable efforts to list all the Registrable Stock covered by such registration statement on the New York
Stock Exchange or the Nasdaq Global Select Market; and 
 (ix) make available to each Investor, as soon as reasonably
practicable, an earnings statement covering the period of at least 12 months, but not more than 18 months, beginning with the first month of the first fiscal quarter after the effective date of such registration statement, which earnings statement
shall satisfy the provisions of Section 11(a) of the Securities Act, including, without limitation, Rule 158 promulgated thereunder. 

 For purposes of Sections 2(c), 2(e) and 2(f)(ii) above, and subject to Section 2(f)(i), the “period of
distribution” of Registrable Stock in an underwritten public offering shall be deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of distribution of Registrable Stock in
any other registration shall be deemed to extend until the sale of all Registrable Stock covered thereby. 
 (g)
Information From Selling Investors. In connection with each registration hereunder, Investors selling Registrable Stock will furnish to the Company in writing such information with respect to themselves and the proposed distribution by them
as shall be reasonably necessary in order to assure compliance with federal and applicable state securities laws. 
 (h)
Underwriting Agreement. In connection with any registration pursuant to this Section 2 that covers an underwritten public offering, the Company and Investors selling Registrable Stock each agree to enter into a written agreement with the
managing underwriter selected in the manner herein provided in such form and containing such provisions as are customary in the securities business for such an arrangement between major underwriters, selling stockholders and a company of the
Company’s size and investment stature; provided, that in the case of any Demand Registration, such agreement shall be satisfactory to WCAS and any other Initiating Investor. 
 (i) Expenses. The Company will pay all Registration Expenses (as defined below) incurred in complying with Section 2 of this
Agreement. All Selling Expenses (as defined below) incurred in connection with any registered offering of securities that, pursuant to this Section 2, includes Registrable Stock, shall be borne by the participating sellers in proportion to the
number of shares sold by each, or by such persons, including the Company if the Company is a seller, as they may agree. All expenses incident to performance of or compliance by the Company with Section 2 hereof, including, without limitation,
all Commission, stock exchange, Nasdaq or National Association of Securities Dealers, Inc. (“NASD”) registration and filing fees (including, without limitation, fees and expenses incurred in connection with the listing of the Common
Stock of the Company on any securities exchange or exchanges or Nasdaq), printing, distribution and related expenses, fees and disbursements of counsel and independent public accountants for the Company, all reasonable fees and disbursements of one
firm counsel for the participating sellers selected by WCAS and, in the case of a Demand Registration, any other Initiating Investor (or, in the event that WCAS is not participating in such registration and such registration is not Demand
Registration, such counsel shall be selected by the Investors holding a majority of the Shares of Registrable Stock proposed to be included in such registration) (the “Investors Counsel”), all fees and expenses incurred in
connection with compliance with state securities or blue sky laws and the rules of the NASD or any securities exchange, transfer taxes and fees of transfer agents and registrars, but excluding any Selling Expenses, are herein called
“Registration Expenses”. All underwriting discounts and selling commissions applicable to the sale of Registrable Stock are herein called “Selling Expenses”. 
 (j) Deferral; Suspension. Notwithstanding anything herein to the contrary, the Company may defer the filing (but not the
preparation) of a registration statement with respect to any Demand Registration or suspend the rights of selling Investors to make sales 

 
pursuant to a registration statement otherwise required to be kept effective hereunder if the Company determines in good faith that there exists a material
proposed transaction (including any proposed acquisition or disposition) or other material non-public information, in each case, that would be required to be disclosed in such registration statement and the disclosure of which would either have a
material adverse effect on such material proposed transaction or the Company; provided, that such delay shall not continue beyond the earlier of (A) the date upon which such material information is otherwise disclosed to the public or
ceases to be material and (B) 90 days after the Company effects such deferral or suspension; provided, further that, in the case of any Demand Registration, the time periods set forth in Section 2(f)(i) shall be tolled for
the period of such deferral or suspension. 
 SECTION 3. Indemnification Rights and Obligations In Respect of Registered Offerings of
Registrable Stock. 
 (a) Company Indemnification of Selling Investors. In the event of a registration of any of the Registrable
Stock under the Securities Act pursuant to Section 2 of this Agreement, the Company will indemnify and hold harmless each seller of Registrable Stock thereunder and each other person, if any, who controls such seller within the meaning of the
Securities Act and each underwriter and each person who controls any underwriter within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several, (or actions in respect thereof) to which such seller,
underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) (i) arise out of or are based upon any untrue statement or
alleged untrue statement of any material fact contained in any registration statement under which such Registrable Stock was registered under the Securities Act, any preliminary prospectus or final prospectus contained therein, or any amendment or
supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) arise out of or are based
on any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law and will reimburse
each such seller, each such underwriter and each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided,
that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage, liability or action arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made
in strict conformity with information furnished by such seller, such underwriter or such controlling person in writing specifically for use in such registration statement or prospectus; provided, further, that the indemnity agreement
contained in this Section 3(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably
withheld). 
 (b) Selling Investor Indemnification of the Company and the Other Selling Stockholders. In the event of a registration
of any of the Registrable Stock under the Securities Act pursuant to Section 2 of this Agreement, each seller of such Registrable Stock thereunder, severally and not jointly, will indemnify and hold harmless the Company and each person, if any,

 
who controls the Company within the meaning of the Securities Act, each officer of the Company who signs the registration statement, each director of the
Company, each underwriter and each person who controls any underwriter within the meaning of the Securities Act, and each other seller of Registrable Stock and each person who controls any such other seller of Registrable Stock, against all losses,
claims, damages or liabilities, joint or several, (or actions in respect thereof) to which the Company or such officer or director or underwriter or other seller or controlling person may become subject under the Securities Act or otherwise, insofar
as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the registration statement under which such Registrable
Stock was registered under the Securities Act, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material
fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and each such officer, director, underwriter, other seller of Registrable Stock and controlling person for any legal or
other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, that such seller will be liable hereunder in any such case if and only to the extent that
any such loss, claim, damage, liability or action arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in strict conformity with information pertaining to such
seller, as such, furnished in writing to the Company by such seller specifically for use in such registration statement or prospectus; provided, further, that the aggregate liability of each seller hereunder shall be limited to the
proceeds (net of underwriting discounts and commissions) received by such seller from the sale of Registrable Stock covered by such registration statement; provided, further, that the indemnity agreement contained in this
Section 3(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of such seller of Registrable Stock (which consent shall not be unreasonably
withheld). 
 (c) Indemnification Procedures. Promptly after receipt by an indemnified party hereunder of notice of the commencement
of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party in writing thereof, but the omission so to promptly notify the indemnifying party shall
not relieve it from any liability which it may have to any indemnified party other than under this Section 3. In case any such action shall be brought against any indemnified party and it shall promptly notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel reasonably satisfactory to such indemnified party, and, after notice from the
indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 3 for any legal expenses subsequently incurred
by such indemnified party in connection with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected; provided, that if the defendants in any such action include both the indemnified party and
the indemnifying party and the indemnified party shall have reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party, or if the interests of the
indemnified party reasonably may be deemed to conflict with the interests of the indemnifying party, the indemnified party shall have the right to select a separate counsel and to assume such 

 
legal defenses and otherwise to participate in the defense of such action, with the reasonable expenses and fees of such separate counsel and other expenses
related to such participation to be reimbursed by the indemnifying party as incurred. Notwithstanding the foregoing, any indemnified party shall have the right to retain its own counsel in any such action, but the fees and disbursements of such
counsel shall be at the expense of such indemnified party; provided that such fees and expenses shall be at the expense of the indemnifying party if (i) the indemnifying party shall have failed to retain counsel for the indemnified person as
aforesaid or (ii) the indemnifying party and such indemnified party shall have mutually agreed to the retention of such counsel. It is understood that the indemnifying party shall not, in connection with any action or related actions in the
same jurisdiction, be liable for the fees and disbursements of more than one separate firm qualified in such jurisdiction to act as counsel for the indemnified party. No indemnifying party, in the defense of any such claim or litigation, shall,
except with the consent of such indemnified party, which consent shall not be unreasonably withheld, consent to entry of any judgment or enter into any settlement of any pending or threatened action in respect of which any indemnified party is or
could have been a party and indemnity was sought hereunder by such indemnified party unless such judgment or settlement includes as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all
liability in respect to such claim or litigation. The indemnification of underwriters provided for in this Section 3 shall be on such other terms and conditions as are at the time customary and reasonably required by such underwriters as
provided in Section 2(h). 
 (d) Contribution. If the indemnification provided for in Sections 3(a) and 3(b) above is unavailable
or insufficient to hold harmless an indemnified party under such Sections in respect of any losses, claims, damages or liabilities or actions in respect thereof referred to therein, then each indemnifying party shall in lieu of indemnifying such
indemnified party contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages, liabilities or actions in such proportion as appropriate to reflect the relative fault of the Company, on the one hand,
and the underwriters or the sellers of such Registrable Stock, on the other, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or actions as well as any other relevant equitable
considerations, including, without limitation, the failure to give any notice under Section 3(c) above. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact relates to information supplied by the Company, on the one hand, or the underwriters or the sellers of such Registrable Stock, on the other, and to the parties’ relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission. The Company and each of the Investors agrees that it would not be just and equitable if contributions pursuant to this Section were determined by pro rata allocation (even if all of the sellers of such
Registrable Stock were treated as one entity for such purpose) or by any other method of allocation which did not take account of the equitable considerations referred to above in this Section. The amount paid or payable by an indemnified party as a
result of the losses, claims, damages, liabilities or action in respect thereof, referred to above in this Section, shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this Section, the sellers of such Registrable Stock shall not be required to contribute any amount, in the aggregate, in excess of the amount, if any, by which the total price
at which the Registrable Stock sold by each of them was offered to the public exceeds the amount of any 

 
damages which they are otherwise required to pay by reason of such untrue or alleged untrue statement or omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act), shall be entitled to contribution from any person who is not guilty of such fraudulent misrepresentation. 
 SECTION 4. Rule 144. The Company agrees with the Investors that, from and after the IPO Date, it shall timely file any and all reports required to
be filed by it under the Securities Act and the Exchange Act and the rules and regulations adopted by the Commission thereunder, or, if the Company is not thereafter required to file any such reports, it shall, upon the written request of any
Investor, make publicly available at all times after 90 calendar days following the IPO Date such information as is necessary to permit sales pursuant to Rule 144 under the Securities Act. Upon the written request of any Investor, the Company shall
promptly furnish to such Investor a written statement by the Company as to its compliance with the reporting requirements as set forth in this Section 4 and such other information as may be reasonably requested in availing any Investor of any
rule or regulation of the SEC which permits the sellers of any such securities without registration. 
 SECTION 5. Duration of
Agreement. Except as provided in Section 2(e), all provisions of this Agreement shall survive so long as any Investor owns any Registrable Stock. 
 SECTION 6. Miscellaneous. 
 (a) Additional Registration Rights. Without the consent of WCAS,
the Company shall not grant any registration rights to any other person that are inconsistent or conflict with the registration rights granted hereunder. 
 (b) Headings. Headings of sections of this Agreement are inserted for convenience of reference only and shall not affect the interpretation hereof. 
 (c) Severability. Each provision of this Agreement shall be treated as a separate and independent clause, and the unenforceability of any one
clause shall in no way impair the enforceability of any of the other clauses contained herein. If one or more of the provisions contained in this Agreement shall for any reason be held to be unenforceable, such provision or provisions shall be
construed by the appropriate judicial body by limiting or reducing it or them, so as to be enforceable to the maximum extent compatible with applicable law, and no other provision hereof shall be affected by such holding, limitation or reduction.

 (d) Benefits of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and permitted assigns and nothing in this Agreement, expressed or implied, is intended to confer on any person other than the parties hereto, their respective successors and permitted assigns, any rights, remedies, obligations or
liabilities under or by reason of this Agreement. The rights and obligations of the parties hereto shall not be assigned without the consent of WCAS, in the case of any assignment by the Company, or the Company, in the case of any assignment by any
Investor, and any attempted assignment in violation of this Section 6(d) shall be null and void; provided, that without the prior written consent of WCAS and the Company, any Investor’s rights and obligations hereunder are
assignable to a transferee in connection with any transfer of 

 
Registrable Stock (including by means of transferring securities that are directly or indirectly convertible into or exercisable or exchangeable for
Registrable Stock) so long as (i) such transferee expressly agrees in writing to become bound hereby as an “Investor” hereunder and (ii) notice of such transfer is given to the Company and WCAS. 
 (e) Entire Agreement; Modification. This Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof
and supercedes all prior agreements and understandings, oral and written, between the parties hereto with respect to the subject matter hereof. This Agreement may not be modified or amended except by a writing signed by the Company and WCAS;
provided, that no provision of this Agreement may be modified or amended in a manner materially adverse to an Investor other than WCAS (in its capacity as an Investor hereunder) if such modification or amendment affects such Investor
disproportionately relative to the other Investors except with the written consent of such Investor; provided, further, that no provision of this Agreement may be modified, waived or amended in a manner adverse to Morgan Stanley or any
of its successors or assignees who become a party to this Agreement in accordance with the terms hereof (collectively, the “Morgan Stanley Investors”) except with the prior written consent of the holders of a majority of Registrable
Stock held by the Morgan Stanley Investors (such consent not to be unreasonably withheld or delayed); provided, further, however, that notwithstanding the foregoing, in accordance with the last sentence of Section 6(d)
above or upon the written agreement of the Company and WCAS, additional Investors may be added to this Agreement (it being understood that any amendment of the provisions of this Agreement in connection with the addition of new Investors to this
Agreement does not require the prior written consent of the Morgan Stanley Investors so long as no provision of this Agreement is amended in a manner adverse to any of the Morgan Stanley Investors). Except as otherwise provided herein, any waiver of
any provision of this Agreement must be in a writing signed by the party against whom enforcement of such waiver is sought. 
 (f)
Notices. All notices, requests, instructions and other documents that are required to be or may be given or delivered pursuant to the terms of this Agreement shall be in writing and shall be sufficient in all respects if delivered by hand or
national overnight courier service, transmitted by facsimile (subject to confirmation by return facsimile of such facsimile transmission) or mailed by registered or certified mail, postage prepaid, as follows: 
 If to the Company, to it at: 
 16825 Northchase Drive 
 Houston, Texas 77060 
 Facsimile: (832) 601-6688 
 Attention: Chief Executive Officer 
 with a copy to: 
 Welsh, Carson, Anderson & Stowe IX, L.P. 
 320 Park Avenue, Suite 2500 
 New York, New York 10022 
 Attention: D. Scott Mackesy 
 Facsimile: (212) 893-9566 

 with an additional copy to: 
 Ropes & Gray LLP 
 45 Rockefeller Plaza 
 New York, New York 10111 
 Attention: Othon A. Prounis, Esq. 
 Facsimile: (212) 841-5725 
 If to any Investor, to such Investor at its address set forth on
Schedule I; 
 or such other address or addresses as any party hereto shall have designated by notice in writing to the other parties hereto. Such
notices, requests, instructions and other documents shall be deemed given or received (i) five business days following sending by registered or certified mail, postage prepaid, (ii) one business day following sending by national overnight
courier service, (iii) the day of sending, if sent by facsimile prior to 5:00 p.m. (EST) on any business day or the next succeeding business day if sent by facsimile after 5:00 p.m. (EST) on any business day or on any day other than a business
day or (iv) when delivered, if delivered by hand. 
 (g) Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Any or all such counterparts may be executed by facsimile. 
 (h) Changes in Registrable Stock. If, and as often as, there are any changes in the Registrable Stock by way of stock split, stock dividend,
combination or reclassification, or through merger, consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof as may be required so that the rights and privileges granted
hereby shall continue with respect to the Registrable Stock as so changed and the Company shall make appropriate provision in connection with any merger, consolidation, reorganization or recapitalization that any successor to the Company (or
resulting parent thereof) shall agree, as a condition to the consummation of any such transaction, to expressly assume the Company’s obligations hereunder. 
 (i) Specific Performance. Each party hereto agrees that a remedy at law for any breach or threatened breach by such party of this Agreement would be inadequate and therefore agrees that any other party hereto
shall be entitled to specific performance of this Agreement in addition to any other available rights and remedies in case of any such breach or threatened breach. 
 (j) Governing Law. This Agreement and all disputes arising out of or relating to this Agreement, its subject matter, the performance by the parties of their respective obligations hereunder or the claimed
breach hereof, whether in tort, contract or otherwise, shall be governed by and construed in accordance with the internal laws of the State of New York. 
 (k) Interpretation. As used herein, the words “hereof”, “herein”, “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this 

 
Agreement as a whole and not to any particular provision of this Agreement, and the word “Section” refers to a Section of this Agreement unless
otherwise specified. Whenever the words “include”, “includes” or “including” are used in this Agreement they shall be deemed to be followed by the words “without limitation”. The definitions contained in this
Agreement are applicable to the singular as well as the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such terms. 
 [SIGNATURE PAGES FOLLOW] 

 IN WITNESS WHEREOF, each of the parties hereto has duly executed and delivered this Registration Rights
Agreement as of the date first written above. 
 THE COMPANY: 
  

			
	US ONCOLOGY HOLDINGS, INC.
		
	By:	 	  
	Name:	 	
	Title:	 	

 WCAS: 
  

			
	 WELSH, CARSON, ANDERSON &
STOWE IX, L.P.

		
	 By:
	 	 WCAS IX Associates LLC,
 its General
Partner

		
	By:	 	  
	Name:	 	
	Title:	 	

 MORGAN STANLEY: 
  

			
	 MORGAN STANLEY STRATEGIC
INVESTMENTS, INC.

		
	By:	 	  
	Name:	 	
	Title:	 	

 OTHER INVESTORS: 
  

			
	WCAS MANAGEMENT CORPORATION
		
	By:	 	  
	Name:	 	
	Title:	 	
	
	 Russell L. Carson
 Bruce K.
Anderson
 Thomas E. McInerney
 Robert A. Minicucci
 Anthony J. de Nicola
 Paul B. Queally
 D. Scott Mackesy
 D. Scott Mackesy
– IRA
Charles Schwab & Co., Inc. Custodian
 Sanjay Swani
 John D. Clark – IRA
Charles Schwab & Co., Inc. Custodian
 John D. Clark
 James R. Matthews
– IRA
Charles Schwab & Co., Inc. Custodian
 Jonathan M. Rather – IRA
Charles
Schwab & Co., Inc. Custodian
 Sean M. Traynor
 John
Almeida
 Rona Drogy
 Dave Mintz
 Clinton Biondo
 Ankar Kumar
 Michael E. Donovan
 Brian Regan
 Eric J. Lee

  

			
		
	By:	 	  
	Name:	 	Jonathan M. Rather
	Title:	 	Attorney-in-Fact

			
	 THE PATRICK WELSH 2004
IRREVOCABLE TRUST

		
	By:	 	  
	Name:	 	
	Title:	 	

	
	
	   
	R. Dale Ross
	
	   
	Lloyd K. Everson, M.D.
	
	   
	Phillip H. Watts
	
	   
	Bruce D. Broussard
	
	   
	George D. Morgan
	
	   
	Leo E. Sands
	
	   
	Atul Dhir, M.B.B.S., D. Phil

			
	ROSS RESOURCES LIMITED
		
	By:	 	  
	Name:	 	
	Title:	 	

 Schedule I to Amended and Restated Registration Rights Agreement 
  

			
	 Investors
	  	 Address for Notices

		
	 Welsh, Carson, Anderson & Stowe IX, L.P.
 WCAS Management Corporation
 Russell L. Carson
 Bruce K. Anderson
 The Patrick Welsh 2004 Irrevocable Trust
 Thomas E. McInerney
 Robert A. Minicucci
 Anthony J. de Nicola
 Paul B. Queally
 D. Scott Mackesy
 Sanjay Swani
 John D. Clark
 IRA f/b/o John D. Clark
 IRA f/b/o D. Scott Mackesy
 IRA f/b/o James R. Matthews
 IRA f/b/o Jonathan M. Rather
 Sean M. Traynor
 John Almedia, Jr.
 Stacey Bellet*
 Suzanne Bellet Price*
 Rona Drogy
 David Mintz
 Clinton M. Biondo
 Ankur Kumar
 Michael E. Donovan
 Brian T. Regan
 Eric J. Lee
 Jill A. Hanau
	  	 c/o Welsh, Carson, Anderson & Stowe
 320 Park Avenue,
Suite 2500
 New York, New York 10022
 Attention: D. Scott
Mackesy
 Facsimile: (212) 893-9566

	*	Additional copy to: 

 125 East 72nd Street

 Apt. 11-D 
 New York, NY 10021 
 Attention: David F. Bellet 
  

			
		
	 Robert A. Ortenzio
 Rocco A. Ortenzio
	  	 c/o Select Capital Corporation
 4718 Old Gettysburg Road,
Suite 405
 Mechanicsburg, PA 17055
 Attention: Robert
Nause
 Facsimile: (717) 972-1080

 SCHEDULE 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 

			
	 Investors
	  	 Address for Notices

		
	 Melkus Partners
 Melkus Family Foundation
 The Lauren Evelyn Melkus Trust
 Lauren Melkus
	  	 c/o Kenneth J. Melkus
 102 Woodmont Blvd., Suite
110
 Nashville, TN 37203
 Facsimile: (615)
383-0104

		
	 Joelle M. Kayden
	  	 c/o Accolade Partners, L.P.
 7900 Westpark Drive, Suite
T-602
 McLean, VA 22102
 Facsimile: (703)
749-7800

		
	 Weigers & Co. LLC
 Betsy Weigers 2002 Unit Trust
 George A. Weigers 2001 Unit Trust
	  	 c/o Weigers Capital Management, LLC
 55 Madison Street,
Suite 680
 Denver, CO 80206

		
	 Kyle M. Fink, M.D.
	  	 PBM 391
 0105 Edwards Village Blvd., C104
 Edwards, CO 81632

		
	 Texas Oncology, P.A.
	  	 c/o R. Steven Paulson, M.D.
 12221 Merit Drive, Suite
500
 Dallas, TX 75251

		
	 R. Dale Ross
 Lloyd K. Everson, M.D.
 Phillip H. Watts
 Bruce D. Broussard
 George D. Morgan
 Leo E. Sands
 Atul Dhir, M.B.B.S., D. Phil
 Ross Resources Limited
 Richard J. Hall
	  	 c/o US Oncology, Inc.
 16825 Northchase Drive

Houston, TX 77060
 Attention: R. Dale Ross
 Facsimile: (832) 601-6688

		
	 California State Teachers’ Retirement System
	  	 7667 Folsom Boulevard, Suite 250
 Sacramento, CA
95826
 Attention: Real Desrochers and Seth Hall
 Facsimile: (916)
229 3790

		
	 Gunners Investment Pte Ltd.
	  	 c/o GIC Special Investments Pte Ltd.
 255 Shoreline
Drive, Suite 600
 Redwood City, CA 94065
 Attention: Andrew
Kwee
 Facsimile: (650) 802-1213

 SCHEDULE 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 

			
	 Investors
	  	 Address for Notices

		
	 Abu Dhabi Investment Authority
	  	 P.O. Box 3600
 Corniche Street
 Abu Dhabi
 United Arab Emirates
 Attention: Abubaker Al Khouri
 Facsimile: (971 2)
626-4616

		
	 A.S.F. Co-Investment Partners II, L.P.
	  	 c/o IBM Retirement Funds
 3001 Summer Street, MD
49
 Stamford, CT 06905
 Attention: Betty Sheets
 Facsimile: (203) 316-2190
  
 With a copy to:
  
 c/o Portfolio Advisors, LLC

9 Old Kings Highway South
 Darien, CT 06820
 Attention: Hugh Perloff
 Facsimile: (203) 662-0013

 SCHEDULE 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]